A mother with her baby in Nepal.
Cover: A group of students receive health education in Uganda.
Photos courtesy of USAID
President Trump speaks to a group in the Rose Garden. 
Photo courtesy of The White House
Executive Summary

Seventeen years ago, when the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) began, an HIV diagnosis was a death sentence in many parts of the world. Now, we have the historic opportunity to make what once seemed impossible possible: controlling and ultimately ending the HIV/AIDS epidemic – community by community.

Since 2003, the U.S. government has saved more than 18 million lives and prevented millions of HIV infections through PEPFAR. Working together with our partners in more than 50 countries, we have moved the HIV/AIDS epidemic from crisis toward control. Globally, PEPFAR has helped replace death and despair with vibrant life and hope. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), AIDS-related deaths have been cut by 55 percent and new HIV infections by 40 percent since their respective peaks in 2004 and 1997.
“American leadership in the global response to HIV/AIDS is clear and as strong as ever through the President’s Emergency Plan for AIDS Relief. ... These efforts have saved more than 18 million lives, prevented millions of new HIV infections, and moved the HIV/AIDS pandemic from crisis toward control – community by community.”

– President Donald J. Trump, November 27, 2019

With strong bipartisan support across three U.S. presidents and nine U.S. congresses, the U.S. government has invested more than $85 billion in the global HIV/AIDS response through PEPFAR and as the largest donor to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). This commitment represents the largest made by any nation to address a single disease in history. But the program has always been more about results than resources. PEPFAR shows the power of what is possible through compassionate, cost-effective, accountable, and transparent American foreign assistance. At every level of PEPFAR, we continually evolve in order to serve those most in need optimally. Through this rigor, PEPFAR has once again significantly expanded our results and impact without increased financial resources (Figure A).

As seen in Figure B, as of September 30, 2019, PEPFAR has supported lifesaving antiretroviral treatment (ART) for nearly 15.7 million people, including almost 700,000 children, helping secure the health and welfare of the family. PEPFAR has enabled 2.6 million babies to be born HIV-free to mothers living with HIV. The program has provided critical care and support for 6.3 million orphans and vulnerable children (OVC) and their caregivers so they can survive and thrive.

PEPFAR has helped prevent HIV infection in men and boys, including by supporting nearly 23 million voluntary medical male circumcisions (VMMC) in eastern and southern Africa. PEPFAR has driven steep reductions in new HIV diagnoses among adolescent girls and young women (AGYW), including declines in every region implementing our pioneering DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) public-private partnership across 10 high-burden African countries.

PEPFAR’s investments also have strengthened the systems that drive effective, efficient, and sustainable health care. PEPFAR has helped train 280,000 health care workers (HCW) to deliver and improve HIV care and other health services. In 2019 alone, PEPFAR invested nearly $900 million on horizontal, above-site health systems strengthening, including more than $141 million for horizontal laboratory systems.¹

These efforts have created a lasting health system inclusive of physical and human resource infrastructure for partner countries to confront other current and future health challenges. They have improved the ability of countries with sizable HIV/AIDS burdens to swiftly address other outbreaks, such as Ebola, avian flu, and cholera, and strengthened the platform for global health security and protecting America’s borders.

PEPFAR personnel around the globe have been the front-line immediate

¹ This includes support for laboratory systems, surveillance systems, human resources for health, and other health infrastructure investments.
response teams confronting critical health issues following natural and other disasters. The U.S. ambassador in each country has been at the forefront of PEPFAR’s success, ensuring a cohesive and coordinated whole of U.S. government approach to the HIV/AIDS response and working with partner country leadership to drive the critical policy changes required to maximize the impact of PEPFAR’s investments for those most in need.

Today, for the first time in modern history, we have the opportunity to control a pandemic without a vaccine or a cure. Achieving epidemic control would be a remarkable accomplishment on its own – saving millions of lives, significantly lowering the burden of HIV/AIDS in countries and communities, beginning to reduce the future costs required to sustain the response, and laying the groundwork for eventually eliminating HIV with the discovery of a vaccine or a cure. At the same time, in reaching this goal, partner countries will learn critical lessons for how to create an effective health care delivery system for both wellness and chronic disease care, which they can leverage to address noncommunicable diseases and other rising health threats.
Accelerating Progress Toward HIV/AIDS Epidemic Control

PEPFAR’s transformative, lifesaving impact is unassailable, but our work is not finished to accomplish our mission. The HIV pandemic continues to evolve in every community and country and PEPFAR uses granular data and surveys to understand and rapidly confront these changes. PEPFAR is constantly changing to address new risk groups, new health challenges, and persistent gaps. The PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017–2020) provides a road map for optimizing every American taxpayer dollar with which we are entrusted for maximum impact.

Under the Strategy, PEPFAR remains committed to accelerate progress toward rapidly reaching HIV/AIDS epidemic control in the highest burden countries through client-centered prevention and treatment. PEPFAR also continues to support HIV/AIDS efforts in more than 50 countries worldwide (Figure C) and ensures access to HIV services by all populations that we serve, including key populations (KPs) and other vulnerable groups.

In advance of World AIDS Day 2019, PEPFAR announced that several countries – including Botswana, Cambodia, Ethiopia, Namibia, and Rwanda – are on pace to control their HIV/AIDS epidemic by the end of 2020. Additional PEPFAR-supported countries could also reach this milestone if they accelerate their efforts, focus resources, and rapidly implement policies at scale to ensure access to client-centered HIV prevention and treatment services for those most in need.

PEPFAR defines attainment of epidemic control as the point at which the total number of new HIV infections falls below the total number of deaths from all causes among people living with HIV (PLHIV) in a country, as illustrated by the example of Eswatini (Figure D), which is on pace to achieve epidemic control by 2020, in large part due to a near halving of its HIV incidence rate between 2011 and 2016.

The latest UNAIDS data show that progress toward achieving HIV/AIDS epidemic control varies widely across countries and regions. In sub-Saharan Africa, many countries in eastern and southern Africa have made the greatest gains; conversely, many countries in western and central Africa continue to lag

Figure C: PEPFAR-Supported Countries Worldwide
considerably behind. We also see evidence of slow, stalled, or even reversed progress in many concentrated epidemics around the world, where the burden of HIV disproportionately affects KPs and other marginalized groups.

Countries that have made the greatest progress share a number of key ingredients for success, such as the following:

- The rapid, data-driven expansion of HIV prevention and treatment services at scale, targeted to high-burden geographies, populations, and ages and translated all the way to where these services are delivered

- Strong partner country political leadership, including in creating a supportive HIV policy environment that allows PEPFAR investments and programs most effectively and efficiently to reach those most in need with client-centered prevention and treatment

- Meaningful engagement of civil society and communities, including PLHIV, faith-based partners, and others

- Continual use of quarterly, monthly, and weekly data to improve implementing partner performance and increase impact

![Figure D: The Pathway to Reaching Epidemic Control (Eswatini)](chart.png)

Ambassador Deborah L. Birx and Dr. Anthony Fauci deliver remarks during a briefing at the White House. Photo courtesy of The White House
“[PEPFAR] has been inarguably one of the most successful investments in health care and humanitarian aid in American history.”

- Vice President Michael Pence, November 29, 2018

PEPFAR SPOTLIGHT: PROGRESS

When PEPFAR was launched in 2003, an HIV diagnosis was a death sentence in much of the world, with entire families and communities falling ill. Over the past 17 years, death and despair have been overwhelmingly replaced with vibrant lives and hope.

With the American people’s generosity, the U.S. has saved more than 18 million lives and prevented millions of HIV infections through PEPFAR. Working together with our partners in more than 50 countries, we have accelerated progress toward controlling the HIV/AIDS pandemic; several PEPFAR-supported countries are on pace to reach this remarkable milestone by the end of 2020.

As of September 30, 2019, PEPFAR has supported lifesaving antiretroviral treatment for nearly 15.7 million people, including almost 700,000 children, helping secure the health and welfare of the family. PEPFAR has enabled more than 2.6 million babies to be born HIV-free to mothers living with HIV. The program has provided critical care and support for 6.3 million orphans and vulnerable children and their caregivers so they can survive and thrive.

PEPFAR has helped prevent HIV infection in men and boys, including by supporting 22.8 million voluntary medical male circumcisions in eastern and southern Africa. Through the PEPFAR-led DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) public-private partnership, new HIV diagnoses among adolescent girls and young women have declined by 25 percent or more in nearly all of the regions implementing DREAMS.

PEPFAR continues to invest more than $900 million annually to strengthen the systems that drive effective, efficient, and sustainable health care. PEPFAR has trained 280,000 health care workers in the last decade to deliver and improve HIV care and other health services, supported more than 3,000 laboratories across Africa, and positioned partner countries to effectively address other health challenges, such as the novel coronavirus, Ebola, H1N1, and cholera.

Countries whose progress has either stalled, slowed, or reversed course typically lack one or more of these vital ingredients. PEPFAR is aggressively tailoring programming according to specific current needs, and is planning for sustaining the gains in panel A (Figure E) countries, accelerating progress in panel B countries, redoubling our efforts in panel C countries, and adopting a fresh approach in panel D countries to catalyze a new era of progress.

The graphics in composite (Figure E; panels A–D) show countries with varying levels of reductions in both mortality (as measured by total deaths among PLHIV) and new HIV infections.

Panel A shows countries that have achieved dramatic declines in both total deaths among PLHIV and new infections as they rapidly approach control of their epidemics, at which point the out-year costs of their HIV/AIDS responses will decrease.

Panel B shows countries where programmatic changes made over the last several years have resulted in an accelerated speed of the declines in both
total deaths among PLHIV and new HIV infections (as indicated by a steepening of the slopes), which puts these countries on the path toward controlling their epidemics in the next 12 months.

Panel C shows countries with large epidemics (e.g., South Africa) where progress must accelerate, countries in conflict (e.g., South Sudan) where the epidemic continues unchecked due to the difficulty of taking programs to scale, and other countries where PEPFAR is beginning to have the type of impact needed to change the course of their epidemics.

Finally, Panel D shows the unacceptably slow progress toward decreasing total deaths among PLHIV due to low access to HIV treatment and policies that prohibit the poor from accessing prevention and treatment services needed, which are inhibiting efforts toward achieving epidemic control. Both formal and informal regressive fees for health services disproportionately affect the poor and the vulnerable; progress in the epidemic will depend on these countries addressing this very specific disparity.

PEPFAR SPOTLIGHT: POLICIES

PEPFAR ensures every dollar is optimized for maximum impact through data-driven policies. This includes by supporting partner countries to urgently address key policy barriers to achieving HIV/AIDS epidemic control.

The PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020) provides a policy road map for expanding client-centered, evidence-based interventions for impact in the geographic areas and populations with the greatest HIV/AIDS burden. As the HIV/AIDS pandemic continues to evolve in every community and country, we continually use quantitative and qualitative data to better understand and rapidly confront remaining challenges in order to achieve our mission.

PEPFAR continues to show the power of what is possible through compassionate, cost-effective, accountable, and transparent American foreign assistance. At every level of the program, we use data to increase program effectiveness, efficiency, and performance with geographic and epidemiologic focus; mobilize increased resource contributions and critical policy changes for impact from partner countries; support local partners for sustainable implementation; and validate outcomes, program costs, and results.

For the past decade, this rigor has allowed PEPFAR to significantly expand our results and impact with little or no budget increase.
Figure E - Panel A: Changes in Mortality and New HIV Infections in Select PEPFAR-Supported Countries

Countries that have achieved dramatic declines in both total deaths among HIV-positive individuals and new infections

- New Infections vs Total Deaths Among PLHIV, Burundi (1990 - 2018)
- New Infections vs Total Deaths Among PLHIV, Ethiopia (1990 - 2018)
- New Infections vs Total Deaths Among PLHIV, Kenya (1990 - 2018)
- New Infections vs Total Deaths Among PLHIV, Rwanda (1990 - 2018)
- New Infections vs Total Deaths Among PLHIV, Zimbabwe (1990 - 2018)
Countries where programmatic changes made over the last several years have resulted in an accelerated speed of the declines in both HIV-positive individuals and new infections.
Countries with large epidemics (e.g., South Africa) where progress must accelerate, countries in conflict (e.g., South Sudan) where the epidemic continues unchecked due to the difficulty of taking programs to scale, and other countries where PEPFAR is beginning to have the type of impact needed to change the course of their epidemics.
Figure E - Panel D: Changes in Mortality and New HIV Infections in Select PEPFAR-Supported Countries

Countries with unacceptably slow progress toward decreasing total deaths among HIV-positive individuals due to low access to HIV treatment and policies that prohibit the poor from accessing prevention and treatment services needed.

A deeper analysis of national survey results and program data reinforce that achieving HIV/AIDS epidemic control requires not only financial investment but also effective collaboration and mutual accountability between partner governments and communities.
“Today, a generation that could have been lost is instead thriving and building a brighter future. PEPFAR has truly been one of the great American triumphs of the 21st century.”

– Secretary of State Michael R. Pompeo, November 27, 2018

Using Data to Drive Impact and Address Key Gaps

PEPFAR remains a global leader in the use of granular data to drive health care results and increase impact. This leadership includes our pioneering use of large population-based household surveys to track progress and identify key gaps toward high-burden countries reaching epidemic control while triangulating survey findings with PEPFAR program data. The results from completed PEPFAR-supported surveys in 13 African countries show that several countries are making significant progress toward controlling their HIV/AIDS epidemics. These countries have translated resources from PEPFAR and the Global Fund into effective, highly impactful programs that transcend poverty and weak health systems to reach clients with critical HIV prevention and treatment services.

In six of the countries surveyed, 68 percent or more of PLHIV are virally suppressed, either approaching or exceeding the UNAIDS 90-90-90 target of 73 percent viral suppression among PLHIV by the end of 2020 (Figure F). Despite this progress, these surveys also have identified key gaps, especially in reaching the first 90 target (knowing your HIV status). In the nine African countries where the surveys show the most progress, knowledge of HIV status ranges from 87 percent to 61 percent among those older than age 15 (Figure F). Comparatively, in these same countries, among those who know their HIV status and are on treatment (second 90 target), 91 percent to 84 percent of those older than age 15 are virally suppressed (third 90 target).

2 90 percent of PLHIV know their status, 90 percent of people who know their status are accessing HIV treatment, and 90 percent of people on treatment have suppressed viral loads.
These surveys reveal significant shortfalls in HIV prevention and treatment programming for women ages 15–24 and men ages 25–34 that require urgent action. PEPFAR continues to focus on these critical gaps including through early implementation of our MenStar Coalition public-private partnership and our ongoing DREAMS programming. In all countries surveyed to date, compared with older adults, lower percentages of young women and young men reported knowing their HIV status, current use of ART, and having viral load suppression. These challenges are compounded by the demographic trends in many PEPFAR-supported countries, where a "youth wave" (and in some countries a “youth bulge”) is resulting in millions more young people who are entering a time in life when they are most susceptible to HIV infection, often without an education or job opportunities. Data also show that we are still disproportionately leaving behind children and KPs in most settings.3

A deeper analysis of national survey results and program data reinforce that achieving HIV/AIDS epidemic control requires not only financial investment but also effective collaboration and mutual accountability between partner governments and communities.

3 PEPFAR utilizes the World Health Organization (WHO) definition for KPs, which includes: men who have sex with men, sex workers, transgender people, people who inject drugs, and people in prisons and other closed settings.
PEPFAR SPOTLIGHT: POPULATIONS

PEPFAR is committed to delivering client-centered, stigma-free HIV services that meet populations most affected by the HIV epidemic where they are with what they need.

To achieve HIV/AIDS epidemic control, we are committed to ensure all ages, genders, and at-risk populations know their HIV status, receive lifesaving HIV prevention and treatment services, and remain on antiretroviral therapy in order to achieve viral suppression, improve their health, and stop new transmissions.

We use data to focus our investments on reaching the highest burden populations, many of which are too often being missed with HIV services. Based on survey and program data, this continues to require particular attention to serving children, including orphans and vulnerable children; adolescents; women under age 25; men under age 35; and key populations.

To address these critical gaps, we address key policy and programmatic barriers to health care access and ensure that the individuals and communities we serve are meaningfully involved in decisions affecting their lives, and that all interventions we provide are informed by and tailored to their specific needs.

These data demonstrate the critical role of a supportive policy environment in partner countries to drive progress, including through the rapid adoption and full implementation at scale of relevant WHO policies. The data make clear that providing client-centered HIV prevention and treatment services is essential to address key barriers to health care access, particularly for populations that programs often miss, such as the most vulnerable and poor.

Delivering on Our Mission

PEPFAR continues to focus and align U.S. government resources and activities toward achieving HIV/AIDS epidemic control by emphasizing the following priorities.

PEPFAR Priorities for Accelerating Progress Toward HIV/AIDS Epidemic Control

- Specific laser focus on delivering client-centered, stigma-free HIV services that meet people where they are with what they need, including finding the people and populations we have been missing, keeping them on treatment, and achieving viral suppression to improve their health and stop new transmissions.

- Continued focus on prevention for impact, with particular attention to reaching children (including OVC), adolescents, women under age 25 (including through the DREAMS partnership), men under age 35 (including through the MenStar Coalition), and KPs.

- Strengthened financial contributions by and improved policy environments in partner countries for HIV/AIDS programs to maximize their impact and sustainability. Ensuring countries implement all WHO policies fully and at scale. Addressing key barriers to health care access by the most vulnerable and poor, such as stigma and discrimination, formal and informal service fees, and sexual violence, including the alarming rates of violence faced by those ages 9–14.
Greater work with and implementation through indigenous partners, including faith communities and faith-based organizations, HIV network organizations, community-based organizations, and community- and KP-led organizations directly servicing those most at risk for and affected by HIV. Increase the percentage of implementing partners that are indigenous organizations at each PEPFAR implementing agency to 70 percent by the end of fiscal year (FY) 2020.

Expand and deepen innovative partnerships with the private sector, multilateral institutions, and other nongovernmental stakeholders to increase impact and support sustainability, including as measured by the PEPFAR Sustainability Index and Dashboard.

Continuous use of the latest, most granular epidemiologic and cost data to improve partner performance, find additional efficiencies, and increase the impact.

Over the past 17 years, PEPFAR has helped bring the HIV/AIDS pandemic from crisis toward control. The following sections provide greater detail on these priorities and other areas of emphasis for PEPFAR in accelerating country progress toward achieving HIV/AIDS epidemic control in 2020 and beyond.

PEPFAR SPOTLIGHT: PARTNERSHIPS

Partnerships are the cornerstone of PEPFAR’s success. We need all sectors and diverse partners working together to achieve our collective goals.

We work closely with partner countries toward achieving HIV/AIDS epidemic control while promoting the long-term sustainability of their responses. We forge strategic partnerships with the private sector that support and specifically complement our prevention, care, and treatment work addressing key gaps in innovative ways.

PEPFAR coordinates with multilateral partners, such as UNAIDS, the Global Fund, and the World Health Organization, to optimize our investments, strengthen partner country leadership and sustainability, and enhance service delivery.

We partner with and strengthen the capacity of civil society and communities, including faith-based communities and organizations, recognizing that successful and sustainable HIV/AIDS interventions must involve, be informed by, and be tailored to those who we serve. This includes ensuring people living with and directly affected by HIV are meaningfully engaged in decisions that impact their lives.

PEPFAR also partners with U.S. chiefs of mission globally and with the diplomatic corps in Washington, D.C., to advance global health diplomacy and connect health impacts to other U.S. foreign policy priorities, including economic growth, trade, education, and political stability.
A family in Ethiopia.
Photo courtesy of USAID
Increasing the Impact and Cost-Effectiveness of Every Dollar Invested

Delivering more with every dollar means that PEPFAR will continue to use data and collaborate with partners to look for the best possible solutions to reach the most people in need of HIV/AIDS services with our available financial resources. PEPFAR disaggregates all of our data by sex, age, and geography in order to target and tailor our efforts to reach the specific and unique needs of those we serve. These data inputs give us not only the clearest picture of the epidemic, but also our teams and partners the ability to respond efficiently to in-country challenges.

The following section focuses on how PEPFAR uses data to monitor progress, identify and address key gaps, document the incredible progress that has already been achieved, and tailor the program to the phase of the epidemic.
Harnessing Data for Maximum Cost-Effectiveness and Impact: Controlling the HIV/AIDS Pandemic

The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) remains a global leader in the use of granular data to drive health care results and increase impact, including through our pioneering use of large national population-based household surveys to track progress and identify key gaps within high-burden countries reaching epidemic control while triangulating survey findings with program data. The survey results also show that progress toward achieving HIV/AIDS epidemic control requires not only financial investment but also effective collaboration and mutual accountability between partner governments and communities.

The benefit of using PEPFAR data and less biased surveys is that these are collected frequently and provide disaggregated data (by age, sex, and geography). Additionally, site-level data collected by PEPFAR partners are owned by the country government and can be used and disseminated as needed. Quarterly reporting and review allow for real-time data use, giving public health program managers increased ability to track the epidemic.

Since PEPFAR started collecting data on key indicators at the site level and by age and sex, data quality has improved significantly, increasing our ability to use these data to inform necessary programmatic shifts.

How PEPFAR Documents Results

PEPFAR’s focus on optimizing impact is a driving force behind global efforts to reach HIV epidemic control. PEPFAR is partnering with the international community to accelerate toward reaching the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets in all five-year age disaggregated populations.
in order to ultimately reach 95–95–95 at the country level. This translates to ensuring 95 percent of all people living with HIV (PLHIV) know their status, 95 percent of all people who know their HIV status are accessing treatment, and 95 percent of all people on treatment have suppressed viral loads (VLs).

Within PEPFAR, teams are asked to assess populations and geographies and design activities and set targets aimed at accelerating epidemic control. To enhance the systematic gathering, analysis, synthesis, and interpretation of program data for routinely measuring progress, PEPFAR has defined a core set of program indicators that are collected and reviewed at least quarterly.

In order to monitor progress in all populations, PEPFAR relies on the quarterly submission of data from all our country teams. It is no longer adequate to collect data at the aggregate level, as the needs of the individual patients within the population differ between and even within the countries. To address these needs, PEPFAR relies on our robust set of monitoring, evaluation, and reporting (MER) indicators that collect site-level programmatic results by age, sex, and in some cases, key population (KP) for each person receiving PEPFAR-supported services at a site.

The most recent version of the MER indicators, Version 2.4, places an increased emphasis on streamlining and prioritizing indicators for PEPFAR programs. The MER strives to drive program monitoring to a more patient-centered approach (Figure 1). Person-centered monitoring refers to a shift from monitoring measuring services (e.g., the number of HIV tests or people on treatment) to monitoring people at the center of their access to linked HIV and health services. In essence, this marks a shift to better support the clients accessing services by focusing more on their individual health outcomes.

Progress toward epidemic control will be successfully measured, in part, through an effective strategic information framework that monitors not only program outputs, but also key outcomes and programmatic impact.

**Global Trends in New HIV Infections**

PEPFAR supports evidence-based HIV prevention and treatment interventions that are designed, targeted, and rolled out strategically in order to ensure that the number of new HIV infections is lower than the number of all-cause deaths among PLHIV – an essential metric in demonstrating epidemic control. Particularly notable is progress made in sub-Saharan Africa (where PEPFAR invests more than 90 percent of our Country Operational Plan [COP] resources). The only region in the world with an increase in new infections is Eastern Europe and Central Asia, where the numbers are primarily driven by increased new HIV infections in Russia.
Over the past five years, there has been tremendous progress toward reaching epidemic control by implementing the UNAIDS 90-90-90 treatment framework for adult men, adult women, and children and dramatically increasing the funding for and focus on effective primary prevention interventions. PEPFAR remains the largest funder of primary prevention interventions, leading the way on delivering voluntary medical male circumcision (VMMC) for boys and men, DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) interventions for adolescent girls and young women (AGYW), access to pre-exposure prophylaxis (PrEP), and condoms for all populations. Globally, PEPFAR has helped replace death and despair with vibrant life and hope; according to UNAIDS, AIDS-related deaths have been cut by 55 percent since their peak in 2004, and new HIV infections have been reduced by 40 percent since their peak in 1997. Even with this progress, there remain numerous serious challenges to reaching full global epidemic control (95-95-95).

As shown in recent national Population-based HIV/AIDS Impact Assessments (PHIAs), reaching 95-95-95 is possible, but maintaining it will be hard, especially given significant barriers to retaining clients in treatment. This problem is compounded by the lack of national...
surveillance and service delivery systems to detect new infections with immediate prevention and treatment services.

Program results through fiscal year (FY) 2019 show that many countries successfully engaged and retained older clients on antiretroviral treatment (ART), aided by the greater likelihood that they show symptoms of the disease. However, younger clients (less than 30 years old) initiated on treatment (Figure 3), most of whom are likely to be asymptomatic, were not as effectively retained as older, symptomatic clients. Moving forward, as the number of new HIV infections continues to decrease and ART coverage with viral suppression among older populations stays above 75 percent, it will be critical to ensure that ART sites are effectively and efficiently managed for the new and younger clients. It will also be essential to use quarterly program data, disaggregated by five-year age groups and sex, along with the updated treatment current indicator, to identify gaps by population and geography.

PEPFAR is focused on continuing to reduce new infections by saturating areas of high HIV burden at the subnational level (i.e., region, district, and subdistrict) with prevention and treatment services, including targeted HIV testing services (HTS). Strategically focused PEPFAR
programs will be able to identify and treat many more PLHIV and reduce new infections by lowering the average VL in supported communities in high-transmission areas.

We will have the greatest impact on the epidemic by ensuring saturation with prevention services in high-transmission zones. These efforts focus on increasing coverage of evidence-based combination prevention interventions among priority populations, including the following:

- Serodiscordant couples
- KPs (including men who have sex with men [MSM], transgender people, sex workers, people who inject drugs [PWID], and people in prisons and other closed settings)
- Tuberculosis (TB)/HIV co-infected patients
- Children
- Pregnant and breastfeeding women (PBFW)
- AGYW and girls through DREAMS and orphans and vulnerable children (OVC) programming

PEPFAR data have highlighted that our programs have historically underserved young men, who fuel the cycle of HIV infection by transmitting HIV to younger women partners. Special efforts to identify and treat men with HIV were launched in COP16–17 and will be a continued area of focus in COP19 and COP20.

In 2018, there were 1.7 million new HIV infections, compared with 3.4 million in 1996 (Figure 6). The annual number of deaths from AIDS-related illness among PLHIV (all ages) globally has fallen from a peak of 1.7 million [1.3 million–2.4 million] in 2004 to 770,000 [570,000–1,100,000] in 2018. Since 2010, AIDS-related mortality has declined by 33 percent. Reaching the 2020 milestone of fewer than 500,000 deaths will require further declines of about 135,000 per year (Figure 7).

The global decline in deaths has largely been driven by progress in eastern and southern Africa, which is home to 54 percent of all PLHIV worldwide (Figure 8).
Figure 6: Adults and Children Newly Infected with HIV

Figure 7: Number of AIDS-Related Deaths, Global, 1990-2018 and 2020 Target

Figure 8: Number of AIDS-Related Deaths, Eastern and Southern Africa and Western and Central Africa, 1990-2018

Figure 9: Number of AIDS-Related Deaths, Regions Outside Sub-Saharan Africa, 1990-2018
Annual AIDS-related mortality in this region declined by 44 percent from 2010 to 2018, to 310,000 [230,000–400,000]; by comparison, annual AIDS-related deaths in western and central Africa declined by 29 percent, to 160,000 [110,000–230,000] over this same period (Figure 8).

Decreasing the absolute number of new infections – and not just incidence – is essential for both epidemic control and fiscal sustainability, as it drives the burden of disease and cost for caring for PLHIV.

While the incidence rate has declined in most PEPFAR countries, the size of the populations most at risk for HIV infection, especially young women, has substantially expanded in the last two decades due to overall population growth, especially among those under age 25. This is particularly the case in sub-Saharan Africa where, due to high fertility rates and improving child survival, the population of 15–24-year-olds is expected to have doubled by the end of 2020 as compared with the beginning of the epidemic.

With the significant growth of the total population of sub-Saharan Africa and a steep increase in the number of young people in the region, we have reached a critical juncture. In this context, our programs must continually improve just to maintain the status quo and must be even more effective to control this pandemic.

PEPFAR continues to increase program effectiveness through enhancing facility-level data disaggregated by sex and five-year age bands to refine our focus on geographic areas and populations most in need of HIV services. This approach is essential to reduce new HIV infections in sub-Saharan Africa, which are otherwise projected to grow by 25–26 million by 2030. Such growth would nearly double the current cost globally to provide lifesaving treatment services, a level of financing that could not be sustained by any combination of financing from the host country, the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), and PEPFAR. At this moment, we have all the tools required to change the course of the epidemic, and we are beginning to see promising results. However, we must continually use granular data and laser focus to maximize the impact of every dollar spent. Otherwise, we will face an epidemic that will once again spiral out of control, reversing our investments to date.
HIV Infections Averted Due to PEPFAR and Global HIV Response

Modeled data suggest that a cumulative total of nearly 16 million HIV infections globally have been averted since the beginning of the epidemic, including 11.3 million HIV infections in sub-Saharan Africa, due to PEPFAR and the global HIV response. However, thanks to data obtained through the PHIAs, the rate of new HIV infections (incidence) is now measured directly and estimated more precisely. Currently six of the 13 high-burden countries have new incidence measures, and for the other seven they are planned or ongoing.

PEPFAR continues to model partner countries’ results with the most recent national data available from UNAIDS using the Goals model, which is a method for costing and resource allocation during the development of national HIV/AIDS strategic plans and investment framework.

Global Prevalence: Refining PEPFAR’s Impact and Progress Toward Epidemic Control

PEPFAR defines national HIV epidemic control as the point at which the total number of new HIV infections falls below the total number of deaths from all causes among PLHIV, with total deaths declining.

Figure 10 shows the relationship in trends of all-cause mortality among PLHIV and new HIV infections in Rwanda. Achieving epidemic control is attainable, as shown in the 2018 Rwanda PHIA, where the country exceeded 73 percent community viral suppression across age/sex bands. This definition of epidemic control does not suggest near-term elimination or eradication of HIV, as may be possible with other infectious diseases, but rather that we can reduce the total number of PLHIV in a population, achieved through the reduction of new HIV infections alongside steady or declining mortality among PLHIV so that it is consistent with natural aging.

We can reach HIV epidemic control through the combination of effective prevention of mother-to-child transmission (PMTCT), effective primary prevention interventions, and effective treatment of PLHIV who continue to thrive and age. Under this scenario, HIV incidence should continue to decline sharply across high-disease-burden countries (Figure 11). Conversely, a country will not be able to maintain epidemic control if program efforts are not sufficiently sustained, in which case new infections can rebound and/or clients will not remain virally suppressed.

As countries achieve 90-90-90 and progress toward reaching 95-95-95, they must shift from HIV case-finding to maintaining those on HIV treatment and keeping them virally suppressed.
Proportionally, the human resources that were needed to support HIV case-finding should be shifted to support treatment retention and continuity of services.

Patient-level information systems are critical in this phase of the epidemic to ensure there is appropriate action at the site and patient levels so that providers are alerted when patients are either no longer being retained in care and/or are virally unsuppressed. Timely implementation of tolerable antiretroviral (ARV) regimens and convenience of HIV services including wait times and drug dispensing are all linked to patient viral suppression.

We know from the PHIAs that PLHIV who are younger, asymptomatic, and more recently infected are predominantly the ones not yet diagnosed. In order to reach these individuals, we need active HIV case-finding through index testing rather than waiting for the individuals to become symptomatic and be diagnosed years later at a facility. For countries with 70–80 percent ART coverage, index testing will help keep them ahead of their HIV epidemic and prevent infections from growing out of control again.

Figure 12 shows the significant declines in new infections and all-cause mortality across all countries in sub-Saharan Africa, which have been achieved primarily through scale-up of ART and prevention including VMMC.

Nearly 16 million HIV infections globally have been averted since the beginning of the epidemic due to PEPFAR and the global HIV response.

Figure 11: Changes in New Infections and All-Cause Mortality Among Individuals Ages 15 and Older

Nearly 16 million HIV infections have been averted since the beginning of the epidemic due to PEPFAR and the global HIV response.
Implementation of the next phase of the epidemic must get to scale in specific countries for long-term maintenance of sustained epidemic control. Program activities that are needed include the following:

- Disease-specific surveillance
- HIV outbreak investigations by use of recency testing
- Durable viral load suppression (VLS)
- Continued focus on retention and the return to treatment of those alive but no longer in care
- Reduction in mortality by providing care to individuals with advanced disease

Generalized population-based approaches should evolve into routine surveillance and case-finding. In parallel, clear analysis at all levels of country and field team program investments must be evaluated, refined, and realigned. Strategic year-by-year shifts in personnel and investment priorities must be directed at sustaining epidemic control. Finally, outcome-oriented discussions (including measurable goals) between each country’s ministry of health (MOH) and ministry of finance (MOF) must be facilitated to ensure long-term, sustained country investments in areas key to sustaining epidemic control.

Students at a primary school in South Africa. Photo courtesy of The Global Fund/Karin Schermbrucker
Countries that have achieved dramatic declines in both total deaths among HIV-positive individuals and new HIV infections

Figure 12: Changes in New Infections and All-Cause Mortality in Select PEPFAR-Supported Countries
Countries where programmatic changes made over the last several years have resulted in an accelerated speed of declines in both total deaths among HIV-positive individuals and new HIV infections.
Countries with large epidemics (e.g., South Africa) where progress must accelerate, countries in conflict (e.g., South Sudan) where the epidemic continues unchecked due to the difficulty of taking programs to scale, and other countries where PEPFAR is beginning to have the type of impact needed to change the course of their epidemics.
Countries with unacceptably slow progress toward decreasing total deaths among PLHIV due to low access to HIV treatment and policies that prohibit the poor from accessing prevention and treatment services needed.

Figure 15: Changes in New Infections and All-Cause Mortality in Additional PEPFAR-Supported Countries
**Strengthening Program Cost-Effectiveness**

**Efficiency**

PEPFAR has all the tools to achieve sustained epidemic control. With appropriate pricing and innovations — and in partnership with the Global Fund, host governments, and civil society — PEPFAR can continue to scale HIV/AIDS programs to achieve epidemic control. This assumes that countries adequately execute their responsibilities and that existing funding from other sources is well coordinated with the PEPFAR program.

**The Right Policies are Fiscally Responsible**

The challenge for the world is to continually increase the number of people on treatment to reach the 90-90-90 treatment targets while at the same time work within a constrained budget environment. PEPFAR continues to generate significant cost savings and has been able to achieve our goals each year. The program has adopted several policies and innovations that enable existing resources to go further. These policies include Test and Start, multimonth prescriptions, same-day treatment initiation, and differentiated service delivery. Given that the rate of viral suppression among those currently on treatment is generally high, PEPFAR is devoting more funding to case-finding.

PEPFAR has completed full rollout of Test and Start policies. The benefits of treatment as prevention are expected to drive 60–80 percent of the HIV incidence reductions necessary for achieving epidemic control. Multiple economic and cost benefit analyses have confirmed the benefit of early treatment to both PLHIV and the broader society. Importantly, untreated HIV is a significant burden to fragile health care systems, and individuals with advanced untreated HIV are high users of health facilities. Substantial gains in education levels, earned income, and improved child mortality can be demonstrated with appropriate and adequate treatment of individuals with HIV.

Test and Start, which is now fully implemented in PEPFAR countries, also enables countries to adopt same-day
initiation of ART. While same-day initiation is not appropriate in every case, wider use of the policy streamlines ART costs and prevents the costs associated with reidentifying an individual who is lost to follow-up (LTFU). Initiation costs are lower when individuals are treated early in disease because this avoids the additional workup and treatment costs associated with treating individuals with advanced HIV disease. Rapid and sustained viral suppression is associated with strong treatment and prevention benefits.

Differentiated service delivery refers to the process of ensuring that individuals get the right care at the right time. Individuals who are stable on ART can be managed with fewer clinic visits and fewer pharmacy pickups. In most cases, stable patients can receive six months of medication at a time and see a clinician yearly. In 2019, PEPFAR continued emphasizing implementation of differentiated models of care and is working clinic by clinic to ensure these models are in place with fidelity. This allows clinic staff to provide higher quality care to sicker individuals and will allow further deployment of the Test and Start strategy without significantly increasing costs.

**New Drug Regimens and Other Commodity Savings**

Dolutegravir (DTG), a new integrase inhibitor, is inexpensive, safe, well tolerated, and leads to rapid reduction of HIV in the blood. DTG has a high barrier to developing resistance, and resistance is rarely described even without complete adherence. For these reasons, PEPFAR is supporting a rapid rollout of regimens containing DTG. DTG can be used for individuals initiating therapy and for those already on treatment, including those who are on a failing regimen. This regimen shift will simplify supply chain management and rapid adoption of differentiated service delivery models.

PEPFAR is also working to lower the costs of other commodities, including laboratory reagents. PEPFAR has achieved impressive reductions in the cost of VL tests, in some cases from $40 per test to as low as $15. Test and Start means that CD4 testing is not required to identify individuals eligible for ART. This has resulted in significant cost savings. The test is now used to identify individuals with advanced disease so that we can deliver a lifesaving package of care to those who need it.
With appropriate pricing and innovations — and in partnership with the Global Fund, host governments, and civil society — PEPFAR can continue to scale HIV/AIDS programs to achieve epidemic control.

Toward Better Cost Data

PEPFAR continues to improve our internal budget practices. This includes reformatting our financial classification to have a consistent set of accurate cost data from budget development and execution to financial reporting. PEPFAR has developed a revised financial classification structure that provides a more comprehensive, flexible, and transparent tracking of our investment.

The classification structure is now common across budget formation, budget execution, and expenditure reporting to allow for tracking of resource allocation against budgeted funding allocations. This allows PEPFAR to adhere to the basic principle that budgets and financial reporting should be tracked in the same way. This expenditure reporting reflects actual activities as opposed to grouping spending by programming that replaces the older Expenditure Analysis process. This classification system will help PEPFAR become more efficient by showing what is actually purchased and how this contributes to the program’s results. Moreover, this financial classification more closely adheres to Global Fund financial classifications and what would normally be in a government’s Integrated Financial Management Information System.

In 2019, PEPFAR continued our collaboration with the Global Fund and the Bill & Melinda Gates Foundation on key economic and fiscal elements of HIV. The development of PEPFAR’s 2019 COPs was informed by better resource
alignment efforts. Each PEPFAR country team had a detailed analysis of Global Fund, PEPFAR, and host-country investments in HIV that was one expression of the working group output. Global Fund Portfolio Manager and MOH officials were also present at the COP meetings, allowing PEPFAR teams to avoid duplication and ensure complementarity of PEPFAR’s investment.

Under the auspices of the Global Fund, Gates Foundation, and PEPFAR working group, we plan to shift to Activity Based Costing (ABC) and Management in many high-burden countries. ABC will enable all entities, including the host government, to understand what the actual cost of services should be, as opposed to only seeing what our implementing partners pay for the service. This is a key piece of the efficiency agenda that will permit all partners to conduct critical analysis of both HIV spending and the health system as a whole. The working group is also gathering better information on non-site level, system investments. By better understanding the degree of site-level subsidies and what systems-level investments have been completed, we can support a more purposeful and informed transfer of greater fiscal and management responsibility from international donors to host-country entities.
A young student in Malawi. Photo courtesy of USAID
Accelerating Access to HIV Treatment

HIV treatment is one of the most cost-effective investments toward controlling the epidemic, both for the health of the person receiving the medication and to prevent their onward transmission of HIV. Science shows that one of the most important factors in the successful treatment of HIV is the early initiation of effective ART. The sooner that a person living with HIV begins treatment, the more intact and effective their immune system remains and the faster they can achieve viral suppression, which virtually eliminates their risk of transmitting the virus.

As of September 30, 2019, PEPFAR has supported nearly 15.7 million men, women, and children on lifesaving HIV treatment. Further, PEPFAR is the world’s largest supporter of children living with and affected by HIV/AIDS. Without treatment, 50 percent of HIV-positive children will die before their second birthday, and 80 percent before turning 5 years of age. PEPFAR is expanding access to pediatric treatment. This includes by identifying and addressing key barriers to diagnosing children living with HIV and working with industry to ensure that more child-friendly ART regimens, that are both efficacious and affordable, are being produced.

The following section focuses on how PEPFAR is accelerating access to treatment for PLHIV while working to address remaining key gaps. We are working closely with communities to create the messaging to bring healthy people into the health care delivery system. This is critical not only for the diagnosis and treatment of early-stage HIV, but also for increasing the broader community’s interaction with the health care delivery system to prevent and treat all diseases.
Adherence and Retention

The goal of treatment for PLHIV is durable viral suppression, which reduces morbidity and mortality and prevents HIV transmission. Retention in treatment is critical to maintaining the health of PLHIV and achieving epidemic control. To reach this goal, it is critical to target interventions to those who have missed appointments or are LTFU as well as to identify additional interventions for special populations and those who are struggling to adhere to treatment and remain in care. We also must closely monitor the implementation and effectiveness of our interventions to determine which ones have the most impact.

We have identified common barriers to retention in care, such as distance to a clinic, clinic congestion and long wait times, and the presence of formal and informal user fees. Individual and social barriers include issues around disclosure, stigma, and lack of social support. Judgmental or disrespectful providers are an additional barrier to care, and an important focus of COP20 is on patient-centered clinical care.

We must implement interventions to promote treatment adherence in order to achieve and maintain epidemic control. The following interventions form the core package of PEPFAR’s approach to durable and effective treatment:

- The complete scale-up of the fixed dose combination of tenofovir, lamivudine, and dolutegravir (TLD) to all eligible PLHIV, including women of childbearing age.
- Differentiated service delivery models tailoring HIV treatment by location, provider cadre, frequency of visits, and package of services depending on individual patient needs. These models reduce congestion at treatment facilities and have been shown to improve patient retention and VLS.
- Multimonth dispensing (MMD), a differentiated service delivery model, has been shown to improve retention in care and reduces the burden at clinical sites. Stable ART patients at treatment sites should be offered six months of ART with refills and enrolled in a fast-track refill model. Children, adolescents, PBFW, KPs, and foreign nationals who meet criteria for being stable on ART should all have access to MMD.

Client-centered services is a critical part of the PEPFAR India strategy. Photo courtesy of PEPFAR India
Facility-level partners will now be required to report two new supply chain indicators semiannually, underscoring the importance of implementing MMD within their HIV/AIDS program.

Programs are strongly encouraged to coordinate timing of appointments for all members of a family/household on ART in order to minimize the burden on clients.

User fees are a barrier to care. Formal and informal user fees must be eliminated for HIV testing, clinical visits, ART, laboratory testing, and medications required for prophylaxis against opportunistic infections or for treatment of advanced HIV disease complications at all PEPFAR-supported clinics.

Provider sensitization to offer respectful and friendly care to patients with an understanding of the needs of each subpopulation (e.g., males, adolescents) is a focus of patient-centered care. Existing qualitative research may help articulate challenges and enablers for PLHIV and may help tailor interventions in the specific context.

Data assessments in COP18 revealed stark and unexpected deficiencies in program growth, a reflection of both inaccurate data on the numbers of PLHIV in care and substantial problems with retention. Figure 16; panels A-D demonstrate the extent of the problem in each country program. In most cases, program expansion was not as expected; in many cases, there was a reduction in the numbers of PLHIV currently on treatment. There are also important differences by age and sex, indicating specific deficiencies that will require targeted interventions.

These data underscore the urgency of tracking retention, in as close to real time as possible. COP20 programs will clarify the extent of the issues with retention by age and sex and develop program interventions for improvement. PEPFAR will monitor performance closely, looking at VLS and at direct and proxy markers for treatment retention.
Figure 16 - Panel A: Trends in Program Growth Compared with Expectations - 2018Q4 to 2019Q3, by Age, Sex, and Country
Figure 16 - Panel B: Trends in Program Growth Compared with Expectations - 2018Q4 to 2019Q3, by Age, Sex, and Country
Figure 16 - Panel C: Trends in Program Growth Compared with Expectations - 2018Q4 to 2019Q3, by Age, Sex, and Country
Figure 16 - Panel D: Trends in Program Growth Compared with Expectations – 2018Q4 to 2019Q3, by Age, Sex, and Country
Differentiated Service Delivery and Adherence Support

There are various barriers to treatment retention and adherence, including issues of access/convenience, stigma and confidentiality, medication side effects, and deeply held belief systems. Adherence may also be challenged by other factors such as substance use and mental health issues. Untangling the specific issues for each client and addressing them directly improves patient outcomes and allows the opportunity to provide additional client-specific services. Different service delivery models are a critical solution to retention and adherence barriers and can address the different needs of clients.

In all cases, patients should receive ART for multiple months at a time. For clinically stable patients, PEPFAR requires that sites have the capacity to dispense ART for six months at a time. It is expected that approximately 80 percent of PLHIV on treatment will be eligible for and given the choice to receive six months of medication at a time. Program requirements such as having a suppressed VL should not be a barrier to access, and programs should not require a suppressed VL for receiving MMD or a specific model of care.

Individuals who are struggling with treatment as evidenced by missed appointments or missed pharmacy pickups require intervention tailored to their needs. Some patient populations require nuanced interventions and integrated services as detailed on page 47. Patients who are more likely to struggle with treatment adherence, such as pregnant women, those recently initiated on therapy, those with high VLs, those with advanced HIV disease, and children and adolescents, should be prioritized for more intensive support.

In addition, some PLHIV may face other circumstances that make treatment for HIV a lower personal priority (e.g., homelessness or another serious medical condition), while others may refuse treatment for reasons that are unrelated to stigma, discrimination, or other barriers. Innovative strategies are needed to address these groups.
Targeted interventions for those who need additional interventions beyond the core package (and are struggling to adhere and attend) include the following:

- Ongoing case management
- Enhanced adherence and VL counseling and education
- Additional contact with health care providers and regular check-in with lay health workers, including home visits staggered at different times, and the use of other forms of communication such as SMS messaging
- The use of community support personnel to address other needs such as mental health issues
- Population-specific interventions, such as KP groups or adolescent spaces

**Viral Load Monitoring**

The goal of ART is virologic suppression, and this should be achievable by all PLHIV. A VL should be assessed at six months after initiating ART and then yearly thereafter. Though many PEPFAR-supported programs have made remarkable progress in achieving 85–95 percent viral suppression, much work remains.

**Figure 17:** FY 2019Q3 Low VL Coverage in the Midst of High Suppression in Some PEPFAR-Supported Countries

Scale-up of VL and early infant diagnoses (EID) has mostly been with conventional, large-scale, centrally placed instruments. This approach has posed some challenges, including long turnaround time and access to testing at the peripheral or community levels. To help address this issue, the World Health Organization (WHO) prequalified the use of two platforms (Cepheid GeneXpert® and mPIMA) for EID and GeneXpert for VL testing at or near the point of care (POC). POC testing for EID and VL could make results available for patient management within hours of specimen collection.
Implementation and scale-up of POC for EID is essential for country programs to reach 90–95 percent of EID by 2 months of age. POC EID was expanded in 2019 and will continue in 2020. In many countries, VLS rates are lower in PBFW than in the total adult population. PEPFAR is prioritizing the use of POC testing to increase its availability and the rapid return of HIV testing results in PBFW, which will improve care and reduce the risk of mother-to-child transmission (MTCT).

**Cervical Cancer Screening**

Cervical cancer is the number one cancer killer of women in sub-Saharan Africa. Women living with HIV (WLHIV) are up to five times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive forms and with higher mortality than those without HIV. Cervical cancer is preventable through the human papillomavirus (HPV) immunization prior to HPV infection, and screening and treatment of precancerous lesions. Given the high rates of mortality among WLHIV due to cervical cancer, PEPFAR developed an age-band-appropriate, comprehensive strategy to reduce cervical cancer risk by 95 percent in WLHIV by every-other-year cervical cancer screening for WLHIV over age 25. Through the Go Further Partnership with the George W. Bush Institute (Bush Institute), UNAIDS, and Merck, announced in May 2018, screening has been provided for more than a half-million women. The original Partnership countries included those with the highest HIV prevalence, including Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe. In COP20, additional countries with large populations of WLHIV were added, including Ethiopia, Kenya, Tanzania, and Uganda. This strategy creates a pathway to ending cervical cancer in WLHIV in sub-Saharan Africa.

**Optimizing HIV Care and Treatment**

All PLHIV should have access to the most effective, convenient therapy with minimal or no side effects. Optimal ART is critical to lifelong adherence, minimal or no medication side effects, and VLS. This is the cornerstone of the PEPFAR program. The WHO released updated normative and derivative guidance documents in July 2019 at the 2019 International AIDS Society meeting. This included updated guidelines for preferred first- and second-line ART. The WHO now recommends DTG, in combination with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone, as the preferred first-line regimen for all adults, including women of reproductive potential. In addition, the updated guidelines recommend low-dose Efavirenz (EFV 400mg) as the alternative first-line regimen for adults and adolescents. PEPFAR continues to recommend TLD as the preferred option for ART and recommends that countries continue with their transition to DTG-based regimens in 2020.

**Pediatric ART Optimization**

PEPFAR and our global partners continue to prioritize making optimal ARV drugs available for infants and children in a timelier fashion. We are working to accelerate the entire lifecycle of pediatric ARV drugs, including drug development and testing, manufacturing, normative guidance, supply security, and program uptake (www.gap-f.org). In an annual meeting convened at the Vatican, all global partners stepped up their commitments to advance pediatric HIV treatment. In 2019, the WHO-updated HIV guidelines ensured that children were not left behind in their recommendations to shift optimal ART for all PLHIV away from non-nucleoside reverse transcriptase inhibitor (NNRTI) backbone to DTG, in combination with a nucleoside reverse transcriptase inhibitor (NRTI) backbone, as the preferred first-line regimen for all adults, including women of reproductive potential. In addition, the updated guidelines recommend low-dose Efavirenz (EFV 400mg) as the alternative first-line regimen for adults and adolescents. PEPFAR continues to recommend TLD as the preferred option for ART and recommends that countries continue with their transition to DTG-based regimens in 2020.
inhibitors (NNRTIs) and toward integrase-strand transfer inhibitor (INSTI)-based regimens, especially DTG-based regimens. Rapid policy adoption and procurement of optimal pediatric ART regimens is a priority for all countries.

**Adult ART Optimization**

DTG-containing regimens are the preferred first-line ART for all PLHIV, including women of childbearing age, due to superior efficacy, more rapid viral suppression, improved tolerability, and higher threshold for resistance as compared with EFV-containing regimens.

The fixed dose combination of TLD is affordable for low- and middle-income countries and minimizes pill burden; it is the recommended ART regimen for all adolescents and adults. All countries should complete their transition to DTG-based ART in 2020. Routine VL monitoring in accordance with WHO recommendations is encouraged, but VL testing should not be a requirement for transitioning to optimal regimens.

**ART Optimization and Case Management for Key Populations**

The barriers to initiation on HIV treatment and retention in care, in particular stigma and discrimination, may be even more challenging for KPs. Differentiated service delivery models are particularly important for initiating and retaining KPs in lifesaving treatment. Differentiated services are intended to expand ART access to community-based settings, inform the models that work for different groups of KPs, and ensure that the small-scale interventions are built into a more integrated and scaled national approach with drop-in centers, integration in ART providers, and satellite clinics through mobile and online efforts. Mainstream efforts for same-day initiation, the shift to TLD, task shifting, and improved case management, as well as more effective viral testing strategies, must be applied through the use of differentiated models in programs where KPs receive treatment. An integrated case management strategy needs to replace approaches where facilities and KP outreach providers do not work together.
For KPs, an integrated case management approach is vital for linking KPs from the community to public health systems to facilitate rapid ART initiation. Comprehensive case management teams – including peer navigators, HIV counselors, clinical staff, and other program staff – can help newly diagnosed or re-engaged ART patients to establish long-term treatment adherence. Peer navigators who often come from the KP communities themselves can establish trusted relationships with KP patients and should receive rigorous training on a wide range of HIV topics, including HIV care and treatment; local health care systems; social and legal systems; motivational interviewing; and stigma, discrimination, and violence reduction and prevention.

HIV Burden and Treatment Response

At the end of 2018, there were 37.9 million PLHIV globally. As treatment programs are implemented across partner countries, PLHIV are able to live longer and more productive lives. Globally, the number of people on HIV treatment and lives saved increased markedly from 2003 to 2018, largely due to the contributions of PEPFAR and the Global Fund, working closely with partner countries. In a majority of countries, the expansion of treatment was slow but steady from 2004 to 2007 (PEPFAR Phase I), after which enrollments on treatment increased. From 2008 to 2010 (beginning of PEPFAR Phase II), enrollments rapidly increased and continued along similar trajectories.

In 2014, PEPFAR partnered with countries to refocus efforts on high-burden areas and started monitoring the epidemic at the community level, accelerating progress with sustainable results. From 2015 to the current reporting period, enrollment increased even more rapidly, in a revenue-neutral manner, as programs increased efficiency and focused on the goal of achieving epidemic control.

The commitment to monitor treatment coverage saves lives and decreases transmission. PEPFAR–supported countries made significant progress in reaching UNAIDS 90–90–90 targets, with at least five countries currently approaching epidemic control. The rapid implementation of evidenced-based approaches.
interventions has been a primary driver of the dramatic declines in new HIV infections and mortality rates. Ongoing success toward controlling the HIV/AIDS epidemic is completely dependent on continuing and accelerating this momentum. Far fewer individuals under age 25 know their HIV status, are on treatment, or are virally suppressed as compared with older adults.

One of the more important milestones toward controlling the epidemic is when the annual number of new enrollments in treatment approaches 80 percent at the national level. This transition point reflects a care and treatment scale-up rate that is successfully limiting the transmission of HIV to uninfected persons. A lower number of new infections suggests that the future influx of patients requiring treatment will be more manageable, smaller, and less expensive – causing the epidemic to contract.

This shift in trends, while important to control the epidemic, does not imply that future efforts can slow down. Any faltering of national treatment efforts may return the trend lines to an earlier, more negative pattern, once again driving up new HIV infections. Any drop in adherence or retention will result in increasing VLs and substantial surges in HIV transmission.

Pediatric Treatment and Orphans and Vulnerable Children – Focusing the Program Toward Achieving an AIDS-Free Generation and Healthy Children

Pediatrics

Over the last several years there has been a dramatic decline in new pediatric infections, but children born infected with HIV are in critical need of lifesaving HIV treatment. In 2018, 1.7 million children under age 15 were living with HIV/AIDS – nearly 90 percent of whom live in sub-Saharan Africa. Without ART, 50 percent of children living with HIV will die before their second birthday, and 80 percent will die before their fifth birthday. In 2018, only 54 percent of children living with HIV had access to treatment.

Saving the lives of children with HIV is not only the right thing to do; it is the smart thing. By treating children early in their HIV infection, they can stay healthy and thrive. Healthy children who can pursue their dreams will grow economies, create jobs, and strengthen their communities for decades to come.

In August 2014, PEPFAR announced the Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative at the U.S. African Leaders Summit. ACT was a two-year initiative to significantly increase the total number of children receiving lifesaving ART in Cameroon, Democratic Republic of the Congo, Kenya, Lesotho, Malawi, Mozambique, Tanzania, Zambia, and Zimbabwe. The $200 million initiative represented a joint investment by PEPFAR and the Children’s Investment Fund Foundation. Strategies and advances developed during the ACT initiative were incorporated into the yearly operational planning not just for the original ACT countries but for all countries where PEPFAR supports pediatric HIV diagnosis and treatment.

As of the end of September 2019, PEPFAR was supporting 700,000 children on lifesaving ART. PEPFAR has also enabled more than 2.6 million babies to be born HIV-free to mothers living with HIV. The program has provided critical care and support for 6.3 million OVC and their caregivers so they can survive and thrive.

There has been a renewed effort to make optimal ARV drugs available for infants and children in a timelier fashion. PEPFAR together with global partners has developed a framework to accelerate the entire lifecycle of pediatric ARV drugs, including drug development and testing, manufacturing, normative guidance, supply security, and program uptake.
Adoption of the WHO guidelines to treat all children and adolescents living with HIV has been a critical step in linking them to the care they need and a major factor in furthering successes in pediatric treatment accelerated under ACT. WHO HIV guidelines ensured that children were not left behind in the recommendations to shift optimal ART for all PLHIV away from older regimens (such as those with nevirapine) and toward better tolerated, more effective regimens (such as those with DTG).

PEPFAR has worked directly with national partners to promote rapid policy adoption and procurement of optimal pediatric ART regimens, which will make it easier for children and families to stay on treatment and to achieve virologic suppression. PEPFAR has expanded the reach of the OVC program to ensure that all vulnerable children have access to HTS, care, and treatment.

In FY 2019, PEPFAR’s response to OVC continued to evolve in response to changes in the epidemic. While the rate of orphaning continued to decline with the expansion of treatment, significant risks and vulnerabilities remain for children and adolescents as a result of HIV/AIDS. PEPFAR’s OVC program serves children in a range of adverse situations, including children who are living with HIV, living with caregivers who are living with HIV, orphaned, at risk of becoming infected, or a combination of these factors.

For the youngest age band (age 0–4), the risks of HIV infection and orphaning have diminished greatly due to the expansion of PMTCT services and adult treatment. Remaining risks pertinent to OVC programs include LTFU of HIV-exposed infants and suboptimal VLS in children.

The OVC platform’s wide network of staff and volunteers support adherence to medication for prophylaxis of transmission and treatment and proper nutrition for infants and young children, and also provide family services such as socioeconomic assistance. For first-time mothers, especially adolescent girls, OVC program case management services that link young mothers to assistance are critical to ensuring that both parent and child remain healthy and AIDS-free.

OVC community networks are also helpful in finding older asymptomatic children who are living with HIV, but whose lack of routine contact with health centers makes them less likely to be diagnosed through traditional clinic-based HIV testing modalities. PEPFAR’s OVC partners are working to improve children’s treatment outcomes by providing home visits and accompanying children to clinics, and addressing the broader socioeconomic needs of families through interventions such as savings and internal lending groups and linking them to government cash transfers where available.

As children become young adults, their risk for acquiring HIV through sexual transmission increases sharply. OVC programs are uniquely poised to address the myriad of factors that put adolescents at risk. Adolescent female orphans, for example, have an earlier sexual debut than their male counterparts (orphaned and nonorphaned). Furthermore, adolescent females orphaned or living with a caregiver who is ill due to HIV have higher rates of transactional or other unsafe sex and higher exposure to physical and emotional abuse.

Violence Against Children Surveys (VACS) in multiple PEPFAR countries show that forced and coerced sex among females can occur at very young ages. To prevent and protect girls from violence, PEPFAR has invested in prevention, detection, and response activities that continued in FY 2019. These activities include child safeguarding trainings for civil society organizations (CSOs), including faith-based partners, and drop-in center staff to help increase
Additionally, PEPFAR has trained gender-based violence (GBV) responders, including clinicians, nurses, community health workers, social workers, and educators, to better identify signs of violence in children and to ensure they know how to appropriately link to care services.

PEPFAR will continue to work with OVC implementing partners to ensure that the most vulnerable, at-risk children receive appropriate HIV testing and access to lifesaving services. PEPFAR regularly evaluates OVC programs to ensure they adapt to the changing demographics of the epidemic and the shifting evidence for core interventions. PEPFAR sets aside 10 percent of the bilateral program funding to address the diverse, complex, and often critical needs of OVC.

Because adolescent girls in sub-Saharan Africa are 75 percent more likely than boys to acquire HIV, OVC programs have also served as a platform for focused efforts such as DREAMS that provide an array of protective interventions (e.g., schooling, economic support, parenting, and GBV services).

**TB/HIV Co-Infection**

Globally, TB is the leading cause of death from a single infectious disease, and PLHIV are 37 times more likely to develop active TB, which remains the most common cause of death among PLHIV. In 2018, TB was responsible for an estimated 251,000 deaths among PLHIV – approximately one-third of all HIV-related deaths. Implementation of the package of evidence-based TB/HIV interventions is a crucial and high-impact investment of resources and a priority for PEPFAR programming in areas with the greatest burden of TB/HIV co-infection.
Ending HIV-associated TB among PLHIV is possible through a combination of widespread ART coverage, early identification and treatment of TB, TB preventive treatment (TPT), and effective infection control activities. The PEPFAR TB/HIV strategy is intended to reduce PLHIV mortality and is based on four objectives:

- Early and effective TB case-finding: all PLHIV must be screened for TB symptoms
- Optimized TB/HIV care: all PLHIV with TB symptoms referred promptly for diagnostic work-up and optimized ART and TB treatment
- Full integration of TB/HIV clinical services TB prevention: TPT for all eligible PLHIV
- Effective infection prevention and control activities

Early detection and treatment are critical for good outcomes. Regular and high-quality TB screening of PLHIV followed by prompt diagnostic testing and treatment are essential to detect and treat TB quickly and effectively. TB screening can be done by incorporating a simple questionnaire that is administered to all patients who present at a facility or are seen in the community. It can also be administered for patients in differentiated service delivery models or by lay counselors or HIV testing providers as part of HIV case-finding or index testing efforts.

### Optimizing Treatment for Patients with TB and HIV

Delays in diagnosing TB disease and initiating TB treatment can prevent PLHIV on ART from attaining viral suppression and reduce their adherence to ART, which contribute to greater morbidity, mortality, and continued transmission of HIV and TB. Accordingly, PEPFAR teams are directed to ensure that all TB patients are tested for HIV, and that all TB patients with HIV are rapidly started on both appropriate TB treatment and ART. Patients should be treated in the same clinic for both TB and HIV to optimize their treatment regimens and minimize potential for drug-drug interactions, streamline monitoring, and avoid confusion for both patients and providers.
Appropriate care of patients with TB and HIV aims to support adherence by minimizing the burdens placed on the patient. This can be best accomplished through a variety of collaborative and integrated models of TB/HIV care to provide ART and TB treatment in the same clinic, as well as adherence support. Adherence support may include addressing barriers to treatment adherence and include but not be limited to peer or other treatment support, identifying and addressing food insecurity or transportation barriers, or using electronic or mobile devices for additional assistance.

TB/HIV integration should be planned in all settings, including PMTCT/maternal child health settings and programs for KPs. Patients with HIV and TB disease should never be made to visit different clinics for treatment; rather, they should be treated by a single provider in a single clinic. Similarly, if patients are enrolled in a differentiated service delivery model, efforts should be made to align TB treatment or TPT, when appropriate, with that patient’s chosen or assigned model for minimal disruption of care. PLHIV with TB disease should be considered for differentiated service delivery models for PLHIV with advanced disease.

**TB Prevention**

TPT has benefits for individuals, but it also has been demonstrated to decrease TB rates at a population level. TPT can reduce incident TB among PLHIV by up to 89 percent when combined with ART and has been shown to independently reduce mortality. Therefore, scale-up of TPT for all PLHIV and eligible household contacts of PLHIV with TB disease needs to be an integral part of the clinical care package. Broader awareness is integral to reduce stigma and discrimination around TB/HIV, increasing knowledge about benefits of TPT among providers and patients and creating demand for services. This can be done by engaging providers, health care worker organizations, and CSOs, and organizing social media campaigns.

As PEPFAR has committed to fully scaling up TPT over COP19 and COP20, all PEPFAR-supported care and treatment programs are fully engaged in aggressive TPT scale-up in their individual countries with timelines for 100 percent achievement within this timeframe. At entry into care, and at each subsequent encounter, all PLHIV should be screened for symptoms of TB disease using standard WHO screening tools, with clear results captured in medical charts or, preferably, a TB screening register.

**Differentiated Service Delivery for TB/HIV**

Differentiated service delivery models for stable PLHIV should include all recommended TB/HIV services provided to PLHIV, including regular TB screening and TPT. Differentiated service delivery models for delivery of TB services can be modified to accommodate children and adolescents living with HIV. PLHIV with TB disease should be prioritized for differentiated service delivery models adapted specifically to PLHIV with advanced disease.

Differentiated service delivery models are recommended in all PEPFAR-supported HIV programs and will be required for PEPFAR programs moving forward, with prioritization of MMD and visit-spacing. Stable PLHIV on ART in these programs may receive ART refills and facility-based clinical monitoring once every three to six months, or they may receive ART refills and/or clinical monitoring more frequently but in the community. For TPT to be delivered to all PLHIV as part of a comprehensive package of HIV care, certain programmatic adaptations must be considered to ensure PLHIV already in these differentiated service delivery models complete a course of TPT.
Students receive health education in Côte d’Ivoire.

Photo courtesy of The Global Fund/Georges Merillon
Focusing Prevention for Impact

During PEPFAR’s 17 years of programming, we have continuously strived to create opportunities for individuals and national governments to prevent as many new HIV infections as possible. This will be key to “turning off the tap” in our quest for epidemic control. As research has advanced and communities have informed program design, PEPFAR has focused our support for prevention interventions on those that yield the greatest level of impact. Biomedical interventions such as VMMC and PrEP have been lined up alongside comprehensive packages like the DREAMS program to address behavioral, social, and biomedical factors that drive HIV acquisition.

In order to reach epidemic control, we must address the underlying social and cultural issues that prevent people from accessing HIV prevention and treatment services, especially unequal protection of human rights and the presence of stigma and discrimination. When any person is stigmatized or unable to access services due to discrimination, the health of everyone in the community is threatened and the epidemic continues to expand rather than contract. The following section focuses on PEPFAR’s commitment to prevention for impact by ensuring those at most risk of acquiring HIV are able to protect themselves from infection.
Prioritizing Prevention of New HIV Infections in Women, Adolescent Girls, and Children

PEPFAR has made remarkable progress in reaching AGYW whose HIV risk has traditionally been overlooked or not properly addressed. Preliminary PEPFAR modeling data in DREAMS show decreases in new HIV diagnoses among AGYW in all DREAMS districts. Despite that positive finding, PEPFAR-funded PHIAs and recent ECHO trial results reveal unacceptably high HIV incidence among AGYW. DREAMS, along with private sector partners, will continue to grow and adapt to ensure girls are Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe.

The growing population of adolescents in sub-Saharan Africa due to the demographic youth bulge and the persistent cycle of HIV transmission between AGYW and young adult men continue to drive new HIV infections in DREAMS-supported countries. We now understand how pregnancy and breastfeeding greatly increase HIV risk. Adolescent pregnancy rates in developing countries are rising due to the youth bulge, lack of family planning availability, provider bias, and a general refusal to acknowledge adolescent sexuality. Four years ago, nearly 1,000 AGYW in sub-Saharan Africa were infected with HIV daily; this has declined to under 750 new infections daily and must continue to decrease. Girls account for more than two-thirds of new infections among young people in sub-Saharan Africa. Now in its sixth year, DREAMS is delivering comprehensive prevention programming to address the multidimensional circumstances that place young women at increased risk of contracting HIV.

The DREAMS core package of interventions goes beyond the health sector to address the structural drivers that directly and indirectly increase girls' HIV risk, including gender inequality, sexual violence, and a lack of access to education. DREAMS fully operates in 15 countries: Botswana, Côte d’Ivoire, Eswatini, Haiti, Kenya, Lesotho, Malawi, Mozambique, Namibia, South Africa, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe. In 2020, South Sudan was provided DREAMS funding to address the HIV risk associated with post-conflict transactional sex/sex work and GBV.

In order to assess progress and lessons learned from DREAMS, PEPFAR looks to a variety of sources – modeling of new diagnoses among AGYW, program data across DREAMS districts, implementation science studies, and observations of DREAMS implementation in the field. PEPFAR announced promising new DREAMS results on World AIDS Day 2019. In the 10 original DREAMS countries, new HIV diagnoses among AGYW have declined by 25 percent or more in nearly all of the regions implementing DREAMS. Program data also indicated that DREAMS reached more than 1.5 million AGYW in FY 2019 alone.

Access to PrEP continues to grow in DREAMS countries. When the DREAMS partnership began, no PEPFAR–supported country was providing PrEP for AGYW outside of research studies. Now PrEP is available to AGYW in most DREAMS countries. Advocacy for expanding PrEP to reach more AGYW continues, but PEPFAR has made incredible progress on this front. In FY 2019, more than 54,000 AGYW ages 15–24 in DREAMS countries newly initiated PrEP, up from 20,000 in FY 2018.

Through technical visits and consultations with country teams, interagency HQ teams identified areas of improvement for DREAMS. This year, strong guidance on finding and engaging the most vulnerable AGYW and improving economic strengthening in DREAMS was provided to refine and improve implementation across countries.
Members of a DREAMS Safe Space group outside a clinic in Rwanda. Photo courtesy of PEPFAR

In DREAMS countries, most AGYW may be vulnerable in some way. However, a systematic and targeted approach to identify the AGYW most vulnerable to HIV acquisition is important for two reasons: 1) to appropriately allocate limited resources for the population that most needs DREAMS programming, and 2) to increase the country’s ability to reach the majority of the most vulnerable AGYW. Therefore, PEPFAR country teams are now required to use consistent eligibility criteria (e.g., multiple sex partners, history of STIs, orphanhood) across partners based on the scientific literature. With the introduction of this requirement, DREAMS countries will be able to focus their resources on the AGYW most vulnerable to HIV.

Economic disparity related to gender inequality is an ongoing and complex driver of HIV. In most DREAMS countries, from a very young age AGYW are at a disadvantage for learning the skills necessary to apply to well-paid jobs and participating in social networks that are helpful in finding jobs, and lack the financial knowledge and connections to be higher earning entrepreneurs.

The current DREAMS economic strengthening programs were reviewed in the 15 DREAMS countries. Meetings with DREAMS beneficiaries revealed many similar stories of sex as a means for survival or supporting a child, or for material goods. If women can earn their own income, they may have more control over when, why, and with whom they have sex. Therefore, PEPFAR has placed a priority on strengthening economic empowerment interventions with the goal of decreasing AGYW’s reliance on transactional sex and strengthening AGYW’s self-efficacy and decision-making power in relationships.

Two pathways to economic independence are commonly pursued within economic strengthening interventions – entrepreneurship and wage employment. Therefore, PEPFAR country teams are directed to implement programs that create opportunities for AGYW in either one or both of these pathways. Any economic strengthening activities in DREAMS are now tailored by age group and include core principles.
supported by the literature (e.g., using market assessments, providing a bridge to employment or starter packs for small businesses). Country teams and DREAMS partners are also being encouraged to prioritize hiring DREAMS beneficiaries for PEPFAR-related jobs, such as community health workers, as part of the wage employment pathway.

The meaningful and continuous inclusion of AGYW in the planning, implementation, and course correction of programs is crucial. Our interactions with DREAMS beneficiaries and ambassadors are essential to understanding how to better implement DREAMS. A strong DREAMS Ambassador program allows DREAMS beneficiaries to see themselves in future positions of authority and provides concrete opportunities for AGYW to earn an income and reach other vulnerable AGYW. DREAMS is utilizing the knowledge of DREAMS Ambassadors by hiring them to coordinate DREAMS at district or regional levels. These positions will benefit the DREAMS programs and elevate a group of young women who are at a systemic disadvantage in the labor market. By providing a platform for and building the capacity of peer leaders, DREAMS has broadened its reach and elevated the needs and issues of AGYW in national and global fora. DREAMS Ambassadors continue to instill in PEPFAR the mantra of “nothing about us without us.”

**Private Sector Engagement**

Private sector and philanthropic partners remain central to the success of DREAMS by contributing their unique expertise and capabilities to strengthen and complement DREAMS programming. Leveraging private sector approaches such as human-centered design and consumer insights, as well as client-centric models of service delivery, have enabled PEPFAR to gain a stronger understanding of AGYW and their needs. For example, Johnson & Johnson, through its market segmentation analytics and support of a peer-to-peer model program, has allowed PEPFAR to better understand the behaviors of AGYW and amplify their voices in a way that is most responsive to their needs. Furthermore, expertise in brand creation, media, and communications, as seen through partnership with Girl Effect, has supported PEPFAR to be more client-centric in reaching youth through the creation of a youth brand in Malawi that delivers key messages on gender norms, equality, and friendship between girls and boys.
Partnering with the private sector has also allowed for catalytic progress toward policy development and new innovations, as is the case with Gilead’s PrEP donation, which enabled discussions with governments on PrEP policies and the expansion of PrEP among high-risk AGYW.

Through the Gates Foundation, the private sector has also brought its neutrality and independence in measuring DREAMS results through implementation science research and impact evaluation studies. This has allowed for a rigorous and credible analysis of how DREAMS is making a difference in the lives of AGYW.

Finally, by partnering with the private sector, PEPFAR has been able to further deliver on our commitment to building the capacity of community-based organizations (CBOs). Through partnership with ViV Healthcare, DREAMS is supporting local CBOs to effectively work with and deliver services to AGYW.

**DREAMS Innovation Challenge**

In order to infuse innovative solutions, support indigenous and community-based organizations, and complement the DREAMS core package of interventions, PEPFAR launched the DREAMS Innovation Challenge in 2016.

The Innovation Challenge had six focus areas: strengthening the capacity of communities for service delivery, keeping girls in secondary school, linking men to services, supporting PrEP, providing a bridge to employment, and applying data to increase impact. Fifty-five organizations were selected to implement innovative solutions found through the Challenge that built upon existing approaches and furthered the DREAMS’ commitment to reducing new HIV infections in AGYW.

Of the organizations selected for the Challenge, nearly 40 percent had never received PEPFAR funding and nearly two-thirds were small CBOs. Examples of solutions that were implemented through the DREAMS Innovation Challenge include: combining PrEP services for AGYW with the distribution of self-testing kits to their male partners; instituting an early warning system to improve girls’ retention in secondary school; and training AGYW in skills linked to employment such as mechanics, financial literacy, and coding.

Over the course of two years, grantees through the Innovation Challenge successfully reached the following:

- 144,479 AGYW with HIV education, awareness, and prevention services through community strengthening
- 103,045 AGYW with interventions to keep them in school
- 9,742 AGYW with PrEP enrollment through increased demand creation activities
- 31,070 AGYW with workforce development trainings, of which 16,813 have been placed in jobs

More than half of the Innovation Challenge implementing organizations have secured additional funding to sustain their programs beyond the two-year period of the Innovation Challenge, with 50 percent classified as indigenous organizations across the 10 DREAMS countries. Furthermore, the Challenge aimed to build the organizational capacity of grantees to strengthen their implementation abilities. At the completion of the Challenge, of the grantees that completed an organizational capacity assessment, 80 percent showed improvement in at least one of the six domains assessed.

The Innovation Challenge was able to support new, innovative solutions to addressing the complex needs of AGYW while strengthening CBOs to effectively deliver HIV/AIDS services to AGYW.
Strengthening Prevention and Response to Child Sexual Abuse

According to several PHIAs and VACS, it is apparent that vulnerability for HIV is linked to sexual violence and begins when children are very young. VACS and program experience also show that children rarely disclose sexual violence when it does occur and that community norms may serve as a deterrent to formal reporting. Thus, preventing sexual violence among 9–14-year-olds and responding to sexual violence among all children to ameliorate its negative consequences are fundamental approaches for preventing HIV. Justice for Children (a priority of PEPFAR’s Faith and Community Initiative) seeks to prevent the perpetration of sexual violence against children and to facilitate disclosure, reporting, and appropriate system responses to cases of sexual violence against children with a focus on holding perpetrators accountable. The initiative accelerates progress toward these goals through several activities, including providing education about sexual violence against children to faith, traditional, and other community leaders, and engaging those who work with and within the justice sector (i.e., law enforcement, child welfare, legal, judicial) to address barriers to reporting, investigation/arrest, and prosecution. Activities also include supporting survivors as they navigate justice systems.

DREAMing of an AIDS-Free Future for AGYW

DREAMS activities and a focus on AGYW remains integral to PEPFAR’s work. PEPFAR is continuously improving DREAMS programming by working with our country teams, our headquarters technical experts, stakeholders, and AGYW themselves to deliver efficient and effective interventions.

DREAMS has driven significant changes in the HIV field. PrEP is now available to AGYW in most DREAMS countries, along with existing comprehensive prevention. Partner governments are renewing their focus on the importance of gender equality and the impact on adolescent health and development. Multilateral and nongovernmental organizations are successfully advocating for greater attention on and investment in AGYW. Most importantly, AGYW are meaningfully and continuously engaged, driving DREAMS implementation and the prioritization of their issues and needs every step of the way. This is the heart of DREAMS and essential to its success. DREAMS is not a moment; it is a movement.

Figure 19: DREAMS Core Package
Preventing Infections in Women

Because women are uniquely vulnerable to HIV acquisition at different times in their lifecycles, PEPFAR programs must ensure that the most evidence-based interventions are available for them at the times when the intervention can provide the most impact. Starting from the expansive reach of our PMTCT programs and moving into the successes seen through DREAMS, the investments made to support women to remain HIV-negative have been a focus of PEPFAR since our inception. As these girls and young women continue to age, the continuum of prevention and treatment services must remain intact so that they can maintain their health – and that of their families – over time.

Women represent the majority of the clients tested and started on treatment within the PEPFAR platform, and maintaining their level of involvement for these interventions is critical. Evidence has shown that GBV and violence against women may act as a barrier to accessing HIV services and adherence. Therefore, it is important to integrate and strengthen GBV programming and trauma-informed services across the programs and platforms where women seek health care services.

Wherever possible we must strengthen the platforms where women seek care to offer enhanced services for them. ANC platforms are where maternal retesting can not only be strengthened, but also utilized as an entry for screening AGYW eligible for DREAMS and PrEP. We can also decrease stigma by linking multiple services across platforms with which women are comfortable, such as scaling up PrEP in an ANC setting where we may promote messages about healthy pregnancies where PrEP is just one piece of the intervention sequence.

Preventing Mother-to-Child Transmission

Global results have shown dramatic improvement in preventing babies from being born with HIV, but much less of an impact on reducing new adult infections, demonstrating a need to refocus on prevention in young adults.
PEPFAR has been enormously successful in PMTCT implementation, dramatically decreasing new pediatric infections and helping mothers living with HIV to enjoy active, productive lives. These programs will continue to be a cornerstone of PEPFAR. Protecting babies and ensuring they remain HIV-free has resulted in significant improvements in under-age-5 survival rates, reflected in the impressive progress achieved toward the Millennium Development Goals. The next challenge is keeping these children HIV-free as they age into adolescents and young adults.

PEPFAR remains fully committed to working toward the elimination of new HIV infections among children and keeping their mothers alive. With PEPFAR support, a cumulative total of 2.6 million infant HIV infections have been averted, allowing these infants to Start Free. More than half of that progress has been achieved since 2013. That means babies are surviving HIV-free and their mothers are staying healthy and AIDS-free to protect and nurture them. As we move toward the goal of elimination of MTCT globally, we also need to focus more on identifying the PBFW who are at the greatest risk of HIV acquisition in order to allow for either prevention or early treatment if infection has already occurred. Given this heightened risk of HIV acquisition during pregnancy and breastfeeding, PEPFAR is increasing our efforts to prevent infections during this period.

PBFW are an important population to address with prevention services, especially PrEP. Need for PrEP in this population has been elevated to the global level, with multiple U.N. organizations and implementing partners looking to improve the quality of services offered to women to facilitate their ability to start – and maintain – this lifesaving intervention. The reason for this heightened interest in providing PrEP in this population is that PBFW have been shown to be at three to four times higher risk of incident HIV infections when compared with their nonpregnant counterparts. In addition to PrEP preventing incident infections in PBFW, it can also prevent MTCT due to incident infections in pregnancy and breastfeeding, which accounts for about 15–18 percent of MTCT. Including PrEP in the MTCT prevention toolkit is an essential component to attainment of elimination of MTCT.
PEPFAR programs are increasing testing of sexual partners of women to identify serodiscordant couples (when one partner is living with HIV and the other is not) and provide treatment for the partner living with HIV and PrEP for the negative partner until viral suppression is achieved in the person. For PBFW in the higher risk age groups or geographies whose partners cannot be tested, PrEP will be offered to prevent infection during this vulnerable period. Scaling up PrEP implementation for PBFW is a key prevention intervention for PEPFAR programs in countries with high prevalence epidemics.

According to a UNAIDS 2018 analysis, 16 percent of infant HIV infections are in children born to mothers who acquired HIV during pregnancy or breastfeeding. Because of an increasing body of evidence showing high rates of HIV transmission during breastfeeding, PEPFAR is prioritizing additional interventions to reach women in this stage of life. One element of this work is an increased focus on scaling up VL monitoring for PBFW to intervene as early as possible to avert potential infant infections and support maternal health.

Through partner testing, ANC clinics are key settings to identify serodiscordant couples to provide interventions that can lower the risk of HIV transmission. Reaching men and identifying those living with HIV has been difficult since asymptomatic men rarely access the health care system, and the ANC platform represents an important access point. In the coming year, PEPFAR country teams will be expanding use of self-testing for HIV in ANC to allow women to provide tests for their male partners who may not be able to accompany them to their ANC visits.

Many mature PMTCT programs now provide opt-out HIV testing to almost all pregnant women at their first antenatal clinic visit (ANC1) with rapid initiation of lifelong ART; this has reduced MTCT rates at six weeks to below 5 percent in many countries. However, overall MTCT rates at the end of breastfeeding are much higher due to suboptimal maternal ART retention and viral suppression among known WLHIV and unidentified, untreated new infections among PBFW who tested negative at first ANC visit and did not receive further HIV testing. Retesting in later pregnancy and during breastfeeding of high-risk women will allow early detection or seroconversion and rapid initiation of treatment.

PEPFAR has invested significantly in PMTCT and provided extensive support for the use of lifelong ART for all pregnant and breastfeeding WLHIV, an approach that leads to the best outcomes for women and their partners and children. PEPFAR has worked to ensure that all supported countries are providing lifelong ART to pregnant WLHIV. Further, through co-leading the Start Free, Stay Free, AIDS Free initiative, PEPFAR and multilateral partners will continue to work toward elimination of MTCT by preventing infections in HIV-free young women and identifying and providing treatment to those living with HIV.

PEPFAR supports an effective PMTCT cascade of interventions – antenatal services, HIV testing, and use of ART for life; safe childbirth practices and appropriate breastfeeding; and infant HIV testing and other postnatal care services – that results in an HIV-free baby and a mother with a suppressed VL. In 2019, PEPFAR continued to ensure that resources are targeted to high-burden areas to ensure strong linkages for pregnant WLHIV to the continuum of care. Rates of ANC uptake differ greatly between communities and countries, and ANC uptake is needed to provide PMTCT services. To address these barriers, PEPFAR uses site-specific data to ensure resources, including linking pregnant and breastfeeding WLHIV to OVC programs to support maternal health and infant follow-up, are focused in the highest burden areas with the
greatest need to maximize the impact on babies and their mothers. The ultimate goal is to encourage ANC attendance for all women and to offer HIV testing to all pregnant women in ANC in our supported areas.

**Preventing New HIV Infections in Young Men: Voluntary Medical Male Circumcision**

VMMC reduces the risk of HIV acquisition for men by about 60 percent and has benefits for the partners of men who are circumcised as well. PEPFAR has supported more than 22 million VMMCs since the program’s inception across priority countries in eastern and southern Africa. Recent technical and programmatic review by the WHO reaffirms continued support for VMMC as a critical HIV prevention intervention. In addition, recent analyses from the PEPFAR-supported PHIs have closely looked at both male circumcision status and HIV incidence, and these data should inform VMMC prioritization to address geographic coverage gaps and maximize the impact of VMMC by targeting men with the highest HIV incidence.

Since VMMC is an elective procedure, safety is the primary consideration. Complications continue to be reported more commonly among those receiving VMMC under age 15, especially in infants. In a recent analysis of Notifiable Adverse Events (NAE) reported through the PEPFAR system, 100 percent of glans injuries and 90 percent of fistulas were reported in the age 10–14 range, primarily in those under age 13. While measures to prevent the use of the forceps-guided technique in those with immature anatomy have reduced the rate of glans injuries, they continue to occur in young clients, and fistulas are difficult to prevent in young clients. Based on the NAE review, severity of glans injuries and fistulas when they occur, and expected timing of pubertal development, PEPFAR is changing the lower age for VMMC to age 15 or below only in those who have reached Tanner stage 3 of sexual development, to minimize risks. No infant circumcision activities will be supported in COP20. Efforts to reach boys and men over age 15 will be intensified, using strategies identified in several countries for identifying older men at risk and supporting them to undergo VMMC.

Since VMMC is an elective procedure, safety is the primary consideration. Complications continue to be reported more commonly among those receiving VMMC under age 15, especially in infants. In a recent analysis of Notifiable Adverse Events (NAE) reported through the PEPFAR system, 100 percent of glans injuries and 90 percent of fistulas were reported in the age 10–14 range, primarily in those under age 13. While measures to prevent the use of the forceps-guided technique in those with immature anatomy have reduced the rate of glans injuries, they continue to occur in young clients, and fistulas are difficult to prevent in young clients. Based on the NAE review, severity of glans injuries and fistulas when they occur, and expected timing of pubertal development, PEPFAR is changing the lower age for VMMC to age 15 or below only in those who have reached Tanner stage 3 of sexual development, to minimize risks. No infant circumcision activities will be supported in COP20. Efforts to reach boys and men over age 15 will be intensified, using strategies identified in several countries for identifying older men at risk and supporting them to undergo VMMC.

Since VMMC is an elective procedure, safety is the primary consideration. Complications continue to be reported more commonly among those receiving VMMC under age 15, especially in infants. In a recent analysis of Notifiable Adverse Events (NAE) reported through the PEPFAR system, 100 percent of glans injuries and 90 percent of fistulas were reported in the age 10–14 range, primarily in those under age 13. While measures to prevent the use of the forceps-guided technique in those with immature anatomy have reduced the rate of glans injuries, they continue to occur in young clients, and fistulas are difficult to prevent in young clients. Based on the NAE review, severity of glans injuries and fistulas when they occur, and expected timing of pubertal development, PEPFAR is changing the lower age for VMMC to age 15 or below only in those who have reached Tanner stage 3 of sexual development, to minimize risks. No infant circumcision activities will be supported in COP20. Efforts to reach boys and men over age 15 will be intensified, using strategies identified in several countries for identifying older men at risk and supporting them to undergo VMMC.


**Prevention of Infection in Key Populations**

Providing adequate coverage of prevention commodities and services to KPs is a critical component of PEPFAR’s response to the HIV epidemic. Effective elements of the prevention toolkit, such as condoms/lubricants and biomedical interventions (e.g., PrEP and medication-assisted treatment [MAT]), should be easily accessible and consistently available to all KP groups.
Prevention services may have greater impact, including earlier, more frequent health service engagement and improved retention, when they are collaboratively designed, implemented, and monitored by members of the communities for which they are intended. KPs contribute to improved service for members of their own communities because they: 1) share experiences of stigma, discrimination, and/or violence, 2) have knowledge about and access to supportive networks of other KPs who can inform outreach and service implementation, 3) are more likely to be comfortable discussing sensitive matters concerning the experiences of being part of socially marginalized (and in many instances, criminalized) groups, and therefore 4) can more easily establish trust with service recipients and gain their confidence. KPs can provide recommendations on ways to improve programs, identify gaps in programming, and help develop solutions.

PrEP

In September 2015, the WHO recommended that “oral PrEP should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention.” PrEP is an effective biomedical prevention intervention for KPs testing HIV-negative. Community-based initiation and refill of PrEP, supported by peer or lay workers through community prevention case management, has been shown to lead to high uptake of and retention on PrEP. Programs must reduce barriers to access PrEP for the first time and enable access to multimonth dispensed PrEP across community-delivery locations. Government decision-makers and program planners are essential for scale-up of PrEP in-country; they should be aware of the improved effectiveness of KP PrEP interventions if community-delivery options are available.

Condoms and Lubricants

Effective condom distribution, counseling, and promotion ensures condoms act as a barrier to sexual transmission for every sexual encounter for KPs. To achieve this, peers and providers must promote skills for KPs to use condoms and lubricants correctly and to build self-efficacy of KPs to negotiate with sexual partners. Free condoms and lubricants should be distributed through sites where KPs are found, such as in drop-in centers, ART and PrEP sites, and hot spot venues including bars and other locations KPs and their sexual partners may gather. Distribution should vary based on need.

MAT has been shown to be a highly effective treatment for opioid dependence, reducing injecting behaviors that put PWID at risk for HIV, preventing HIV transmission, and improving retention on HIV treatment. For MAT to have an impact on the overall HIV epidemic, services need to reach, provide prevention interventions for, test, treat, and retain as many PWID as possible. As such, HIV testing and ART provision should be integrated into care settings that provide MAT. For countries that have recognized recent increases in HIV among PWID, or in specific subgroups such as young PWID, it is important to implement MAT service delivery models that are responsive to local conditions. MAT services can be delivered in primary health care settings or in specialized outpatient clinics offering treatment to clients with respect and dignity.

Medication-Assisted Treatment

PWID are among the groups most vulnerable to HIV infection. According to WHO guidance, PWID should have access to sterile injecting equipment through needle and syringe programs, and those who are dependent on opioids should be offered and have access to MAT. In addition, these services should integrate or link to HIV-specific services, including testing and treatment.
A mother with her child in Ethiopia.
Photo courtesy of USAID
Leveraging Partnerships for Sustainability

PEPFAR forges strategic public-private partnerships (PPPs) that support and complement our prevention, care, and treatment work addressing key gaps in innovative ways. PEPFAR also advances global health diplomacy through close engagement with U.S. chiefs of mission globally and with the diplomatic corps in Washington, D.C., as well as by connecting health impacts to other U.S. foreign policy priorities.

Since our founding, PEPFAR has built health infrastructure and strengthened capacity through an emphasis on sustainability. We have invested in laboratories and well-trained laboratory specialists critical to well-functioning health systems, enabling clinicians and health workers to better diagnose and treat a range of diseases and conditions. To date, PEPFAR has trained nearly 280,000 health care workers (HCWs) to deliver HIV care and other health services.

No entity alone can control and ultimately end the HIV/AIDS pandemic. It requires all sectors and partners working together to provide financing, demonstrate political will, and carry out interventions both within and outside of the health sector. The following section focuses on how PEPFAR is leveraging our platform and partnerships for sustainability and to accelerate progress toward achieving epidemic control.
Driving a Sustainability Agenda with Country Partners

The global response to the HIV pandemic has been unprecedented. Billions of dollars and millions of people were quickly mobilized to save lives and fight the pandemic. The gains have been tremendous. If country governments, donors, and civil society work in partnership and continue to ensure every investment has a clear outcome, it is within our grasp to control the epidemic. Yet, this potential success is at risk if we do not take decisive actions to ensure the HIV response is sustainable. A series of concrete actions are available that will have rapid impact and accelerate our progress toward long-term sustainability.

Given the magnitude of our contributions to the global HIV response, PEPFAR plays a major role in determining the future path of the HIV epidemic and bears great responsibility for ensuring that the HIV response is sustainable. Indeed, all PEPFAR investments move us closer to sustainability; only an epidemic that is shrinking and not expanding is financially and programmatically sustainable. Ultimately the achievements of PEPFAR will be measured by our contribution to sustained control of the HIV epidemic. However, PEPFAR is not in this alone, and all HIV development partners must do their part. As a key element of our partnerships with country programs, PEPFAR needs every country to commit to making the systems investments required for sustainability through increased resources and mutual accountability for results. In addition, all partner countries must address any poor policies, governance, and service delivery environments that increase stigma and discrimination and create costly artificial barriers to reaching and sustaining epidemic control.

Table 6 – Operationalizing Sustainability

PEPFAR’s core business processes embed sustainability principles and programming into our annual COPs. As part of the COP process, PEPFAR country teams assess the major policy and systemic gaps that inhibit attainment of the 95–95–95 treatment goals and longer term programmatic sustainability. Any barriers that are identified are analyzed and distilled in Table 6, which then enables teams to program so that they are better positioned to overcome those barriers.
One of the principal benefits of Table 6 is that it enables its users to group together several multiyear components or activities and align them with indicators that show annual progress toward various long-term goals. Another is that Table 6 compels its users to consider future or steady state goals as it engages in present day budgeting and programming. This enables the country team to be more purposeful and accountable with their systems investments, setting annual system targets and benchmarks that align with annual treatment and service goals. For example, a team may diagnose weaknesses in a laboratory system that will require the development of new labs, equipment purchases, new supply chains, and capacity building to operate the labs. The latest Table 6 format groups the activities logically and assigns benchmarks that monitor the scale-up and functioning of the new system while ensuring that the varied activities are coordinated and sequenced properly. PEPFAR continues to validate and update the annual indicators to ensure they remain well aligned with desired programmatic outcomes.

With the natural lag between science and implementation, Table 6 also supports efforts to ensure that advancements in science and preferred policies are quickly adopted and completely implemented. Investments captured in Table 6 and the planning and approval process facilitate rapid identification and adoption of policies and programming to speed their implementation. Notably, the rapid adoption of the Test and Start policy, which calls for PLHIV to start ART as soon as they are diagnosed, was significantly accelerated through PEPFAR’s focus on this critical policy. The speed at which this occurred was likely due in part to its emphasis in Table 6.

**The Sustainability Index and Dashboard – a Road Map to Transfer Responsibility**

Table 6 also helps operationalize the Sustainability Index and Dashboard (SID). For PEPFAR, sustainability of the HIV response means that a country has the enabling environment, services, systems, and resources required to effectively and efficiently control the HIV epidemic.

The SID is a measurement tool that provides a framework and periodic snapshot of the elements central to sustainable epidemic control. The biennial requirement that teams complete the SID enables PEPFAR to objectively track progress across many critical sustainability goals.

The SID targets 17 elements organized under the four following overarching domains:

- Governance, leadership, and accountability
- National health system and service delivery
- Strategic investments, efficiency, and sustainable financing
- Strategic information

The specific elements, indicators, and milestones included in the SID measure key areas including, for example, to what extent partner countries mobilize domestic financial resources for their HIV response and allocate those resources strategically and efficiently; whether they have an adequate laboratory system that provides accurate and timely results to patients; and if they ensure a secure, reliable, and adequate supply and distribution system for drugs and other commodities needed to achieve sustainable epidemic control. During the 2019 cycle, two new elements were added: market openness and data for decision-making ecosystem.

The most recent SID review was completed by PEPFAR teams in collaboration with key stakeholders in September and October 2019. Country SIDs are publicly
available and have proven to provide an important foundational base of information for governments, other donors, and civil society that helps them to determine where efforts and/or funding are most needed in order to reach sustainable epidemic control. The 2019 scores will be used to inform assessments of key barriers, which in turn should enhance the effectiveness of Table 6 systems investments.

This year, SID scores showed that most countries’ programs improved their sustainability, although in many places, important gaps remain. Average scores improved across 14 of the 15 elements that were in place in both the 2017 and 2019 SID cycles, although many showed very modest increases. One concerning sign is that across a variety of countries, the degree of cooperation between civil society groups and governments has deteriorated. A vibrant civil society remains necessary to ensure that appropriate investments are made in activities to sustain epidemic control.

**Sustainable Financing as a Key Priority**

A stable financial resource base, mobilized both domestically and externally, is essential for sustainability and critical for long-term planning and decision-making. Because funding will always be limited, the impact of each dollar must be maximized by ensuring that investments are strategic, effective, and cost-efficient.

For PEPFAR, financial sustainability is located at the intersection of epidemiology and economics. It is the ability to initially afford the effort to reach epidemic control, and to then secure a stable funding source that will support health systems that will continue to provide HIV treatment and prevention services to maintain epidemic control after it is achieved. To ensure that the necessary financing is available, PEPFAR is doing the following:

- Focusing on the efficient use of existing resources to ensure that maximum performance is achieved with limited funding
- Standardizing and sharing budget and expenditure data with the Global Fund, partner governments, civil society, and other donors to develop a complete picture of HIV financing
- Engaging MOFs to ensure comprehensive HIV programs are developed and funded in national budgets, with increasing proportions funded by host-country governments over time
- Working with partner governments and civil society to develop key systems, including secure procurement and supply chains and financial management systems, to maintain services and sustain epidemic control
- Ensuring that the private sector has space to thrive and take on elements of the HIV response

In FY 2019, the PEPFAR program continued to embed sustainability and domestic financing elements in our work. This began with the goal of having 70 percent of PEPFAR resources channeled through indigenous organizations by the end of FY 2020. These organizations are better attuned to the needs of the client and can provide a bridge from international efforts to homegrown capabilities, while international donors are still actively engaged in the HIV response and can respond if local efforts have difficulties getting started.

PEPFAR has also started to shift our focus away from tracking resources by spending category and toward tracking spending by intervention and activity. To achieve and maintain epidemic control, specific activities must be funded and executed. Without a detail of these activities, mere commitments of funding to program areas
do not mean critical services will continue. To aid with the categorization of spending, PEPFAR developed a new Responsibility Matrix tool, which charts whether PEPFAR, the Global Fund, or domestic entities have responsibility for specific activities. This places less emphasis on what specific dollar amounts are spent by which funders and instead focuses on whether they have fulfilled the responsibilities to which they have committed. For example, this would enable users to appropriately credit governments that chose to integrate a function or activity into existing structures instead of budgeting a specific amount for an activity.

Related to this, PEPFAR has also worked to integrate Activity-Based Costing and Management (ABC/M) techniques into our budgeting and management processes. To date, PEPFAR has led an international dialogue to generate a consensus approach and methodology to applying ABC to health systems, and will work through FY 2020 to launch ABC in multiple countries and support other organizations like the Global Fund and UNAIDS to implement the agreed-upon approach in additional countries. ABC/M will enable PEPFAR and host governments to drive efficiencies in the health system, both overall and related to specific HIV activities. It will also help to tease out the actual costs of services and enable PEPFAR to reduce our spending to what is necessary, while also giving host governments clearer ideas of the PEPFAR subsidies they have received, and consequently, how much they will have to provide as donors transition out of their current roles.

PEPFAR has also further refined our work on sustainability in countries with concentrated epidemics, such as those comprising our Asia Regional Program. In these countries, PEPFAR has focused on expanding the toolkit for sustainable financing solutions beyond social contracting (where governments contract with nongovernmental organizations to provide services) to social enterprise arrangements (where communities band together to provide services for their members and subsidize the needs of patients who are unable to pay). Social enterprises do not require the same amount of political will for funding that social contracting arrangements require.

A group of children in Guatemala. Photo courtesy of USAID
One additional area of progress during the past year is PEPFAR’s deepening engagement with the Global Fund on matters of sustainable financing. Together, we have comprehensively mapped our two financial systems and agreed to a new methodology to characterize domestic investments that support HIV. For COP19 development, PEPFAR and the Global Fund were able to provide a complete picture of investments to ensure complementarity of action. In addition, Global Fund portfolio managers were involved in this year’s COP planning from the outset to ensure that program changes were coherent and consistent. Near the end of COP18, PEPFAR and the Global Fund also fully harmonized our respective expenditure data, which now give even further insight into how programming evolves after initial budgeting. An interorganizational economic working group meets quarterly and has focused on accomplishing a number of critical goals, which include the further alignment of resources and expenditures ensuring that differentiated service delivery is fully implemented, and better coordinating work with finance ministries. Our two organizations have also shared the progress and benefits of these efforts with other key stakeholders, including UNAIDS, WHO, and UNITAID.

### Building a Data Platform

Transparent, accurate, and timely health, epidemiologic, performance, and financial/expenditure data are essential for making informed and impactful investments that drive long-term improvements in health care services and systems and lower costs. In addition, they allow for the type of active surveillance that allows a country to respond quickly to outbreaks and contain them before they get out of hand. Access to data builds ownership, enhances problem solving, promotes accountability, and allows for real-time decision-making that get a country to epidemic control.

To achieve sustainable epidemic control, PEPFAR is complementing our efforts to enhance MOH data capacity by forging innovative partnerships to support countries in building robust wider data systems that engage all stakeholders, and leveraging these systems to accelerate, focus, and sustain the HIV response.
The Data Collaboratives for Local Impact (DCLI) partnership between PEPFAR and the Millennium Challenge Corporation empowers individuals and communities to use data to improve health, education, gender equality, and economic opportunity while building the foundation for sustained and sustainable control of the HIV epidemic.

Africa’s growing youth population represents not just a demographic challenge to achieving and sustaining HIV/AIDS epidemic control, but also a source of energy and know-how in harnessing the data revolution to end the HIV epidemic. PEPFAR, the Global Partnership for Sustainable Development Data (GPSDD), and Sustainable Development Solutions Network – Youth (SDSN-Y) have joined forces to launch MY DATA (Mobilizing Youth on Data for Action and Transformation in Africa). MY DATA is an informal network for PEPFAR’s partners and like-minded organizations to share best practices and develop new partnerships for inspiring young people as data champions. MY DATA highlights youth engagement across the “data value chain,” from citizen mapping to support HIV/AIDS programming to the use of arts, music, dance, TV, radio, and print journalism to convey data-driven messages about sexual violence. PEPFAR’s leadership through our support for efforts like DCLI, GPSDD, and MY DATA is ensuring efforts to end the AIDS epidemic are firmly embedded in the DNA of emerging data ecosystems, which will be central in opening opportunities for current and future generations.

Engaging Partner Governments and Civil Society

For PEPFAR, sustainability means that a country has the laws and policies, services, systems, and resources required to effectively and efficiently control the HIV epidemic. Sustainability demands a long-term effort to ensure that a country establishes and maintains requisite levels of fiscal ability, technical capability, political will, and citizen engagement. PEPFAR uses a sustainability framework that emphasizes a drive to control the epidemic to the point that the remaining disease burden ultimately can be financed by a host country’s resources and managed with its own technical capability. In the past, PEPFAR has emphasized formal partnership frameworks to drive host-country stakeholders toward sustainability and self-sufficiency. Now, PEPFAR emphasizes that partnerships should be informally embedded in all aspects of program development and execution. Embedding partnerships into daily operations encourages shared responsibility that engages all country stakeholders to develop a system that fits their needs and realities, with an eye toward full host-country responsibility in the future.

Engagement with civil society, including faith-based organizations (FBOs), is a strong driver of sustainability. PEPFAR encourages the full participation of civil society in every stage of our programming and planning, from advocacy to service delivery, as it is a key to the success and sustainability of PEPFAR and the global effort to combat HIV. Civil society has been a leading force in the response to HIV since the beginning of the epidemic, and this longstanding involvement has resulted in expertise and relationships with local communities that nonindigenous organizations often struggle to achieve. It is critical to ensure that community and civil society are meaningfully engaged and have a voice at the decision-making table.

Efforts to embed partnerships in normal program operation start with the development of an operational plan. Partner governments and a variety of local, regional, and global CSOs were involved in the development, planning,
and approval of the 2018 COPs. Feedback provided from CSOs during previous cycles was to include them earlier in the COP planning and approval process.

Quarterly performance reviews are similarly shared with in-country stakeholders, including governments and civil society at the national and local levels. We have developed the PEPFAR Oversight and Accountability Response Team (POART) process, which is a quarterly review of progress to identify weaknesses and areas that require midcourse adjustments. Results are reviewed in person with partner country stakeholders and are integral to identifying problems and bottlenecks that inhibit performance and mitigating problems with appropriate solutions and actions.

While PEPFAR continues to increase our efficiency and transparency, PEPFAR country teams will further expand their collaboration with local civil society, including activists, advocacy groups, and service delivery organizations, to ensure they are actively engaged in PEPFAR processes and in the country-level HIV/AIDS response. PEPFAR will also work to do the following:

- Expand PPPs to address critical issues and challenges faced by KPs
- Ensure that programs such as the Key Populations Investment Fund, the Faith-Based Initiative, and the Elton John LGBT Fund scale up quality HIV/AIDS prevention, care, and treatment programs
- Continue to work with stakeholders and host governments to address social and structural factors (such as stigma, discrimination, violence, and human rights violations)
- Work more closely with partners such as community and civil society organizations, governments, UNAIDS, the Global Fund, and others to strengthen and coordinate efforts

As PEPFAR countries move toward more sustainable programs and transition
to local ownership, many national governments will depend on civil society to an even greater extent to meet the health needs of their citizens. Meaningful engagement with PEPFAR builds the capacity of local CSOs to meet this challenge, better preparing them to play a leadership role now and in the future.

**Robert Carr Fund (RCF)**

PEPFAR was a founding supporter and remains the largest donor to RCF, an international pooled funding mechanism that strengthens global and regional civil society networks in their delivery of HIV services and as champions for the inclusion and social well-being of marginalized people. RCF provides both programmatic and core funding to international civil society networks, paying particular attention to inadequately served populations — the communities and populations most in need of effective HIV prevention, treatment, care, and support. These communities include PLHIV, gay men and other MSM, people who use drugs, prisoners, sex workers, and transgender people.

RCF grantees often leverage RCF funds to secure funding from other sources, thereby stretching the impact of each PEPFAR dollar spent through RCF. Through RCF, PEPFAR also continues to demonstrate our support for civil society. As RCF’s largest donor, PEPFAR has committed $15 million for 2019–2021, an increase from earlier replenishment cycles.

PEPFAR works with UNAIDS to support RCF and its networks to strengthen our collective HIV response. RCF’s capacity building efforts are linked to health outcomes to ensure it continues to invest in the right activities and networks.

Some recent RCF achievements using PEPFAR funds include the following:

- Thirty-three percent of networks influenced changes in access to or quality of services for inadequately served populations, including increased access to routine VL testing in parts of Latin America; increased access to harm reduction services in Egypt, Jordan, and Lebanon; and reduction of stigma from service providers for transgender women in Latin America and migrants in Asia.

- Twenty-five percent of networks influenced changes in legal and policy environments to better respect and protect and more effectively reach inadequately served populations.

- In environments not conducive to overt efforts to change policy, grantees worked to raise awareness and mobilize international civil society and multilateral organizations to oppose rights violations for better provision of HIV services.

- Grantees built core organizational capacity, allowing governance structures to be reviewed and dramatically improved.

**Key Populations Investment Fund (KPIF)**

During the 2018 International AIDS Conference, PEPFAR reaffirmed our deep commitment to expanding KPs’ nondiscriminatory access to quality, lifesaving HIV prevention and treatment services through the two-year, $100 million KPIF, which is being distributed through the U.S. Centers for Disease Control and Prevention (CDC) and USAID.

KPIF is designed to extend the ability for local KP-led, trusted, and competent implementing partners (IPs) to contribute to PEPFAR’s scale-up of differentiated HIV/AIDS prevention, care, and treatment services for KPs. Where there are not available capacitated KP-led
partners, the KPIF will support local KP-competent IPs and KP-led subrecipients. While supporting greater involvement of local organizations at the community and national levels, the funding will scale up innovative, evidence-based strategies to achieve epidemic control for KPs. PEPFAR currently funds several local IPs through CDC and USAID COP-funded programs that provide effective and scalable HIV services to KPs.

**Core Elements**

- Increase KP testing coverage and HIV case-finding through confidential KP-competent self-testing, index testing, and social network testing strategies
- Scale PrEP through community- and facility-based models
- Enroll more KPs on treatment: scale up KP-competent ART services, rapid ART initiation, community ART provision, and treatment literacy among KPs and their families; strengthen peer navigation and monitoring systems; and reduce stigma and discrimination in both KP-specific ART sites and more mainstream clinical sites
- Retain KPs and achieve VL suppression: scale up peer navigation, address local bottlenecks in the VL process, and provide differentiated service delivery options to ensure HIV-positive KPs are adherent and achieving >90 percent VLS
- Address specific structural barriers that inhibit access to and the effectiveness of HIV services, including violence, legal, law enforcement, policy, economic, and educational barriers
- Scale Undetectable=Untransmittable (U=U) messaging to emphasize the power of sustained ART to reduce HIV infectiousness, discrimination, and HIV self-stigma
- Strengthen the capacity of KP-led indigenous organizations to implement and document the success of community-focused HIV and wrap-around services
- Monitor results in real time: ensure that data are compatible with PEPFAR MER indicators and implement real-time dashboards for use by peer workers and lowest level delivery venues
- Measure and report KPIF-specific impact on operational unit-level efforts to control HIV epidemics, reporting on MER indicators and customized indicators to detail success of structural interventions and capacity-strengthening activities.

Where KPIF activities identify and document effective solutions for reaching, testing, treating, and achieving VLS among KPs, these solutions are prioritized for rapid scale-up and implementation.

**Engaging Faith-Based, Locally Based, and Minority Partners**

Ending AIDS by 2030 requires that all sectors of the global community work together, including FBOs, locally based partners, and minority-serving institutions.

**Faith-Based Organizations**

PEPFAR’s success has been built in partnership with community, including FBOs, and faith-based and traditional communities. Since 2003, FBOs have been included among PEPFAR’s essential partners and remain key partners to accelerate and sustain epidemic control. For persons who do not routinely intersect with medical systems (e.g., boys, men, nonpregnant women, adolescents), we must work with communities to help find them. But community case-finding
efforts are often haphazard, and efforts to build community structures are expensive; it would be far more efficient and productive to access community structures already in place.

In most countries where PEPFAR operates, 60–75 percent of the population regularly attends some form of religious services and/or participates in religious community. These communities of faith are deeply embedded regionally, with national structures, and often have unique institutional capacity and established, durable relationships of trust. Utilizing the expertise of PEPFAR programming and leveraging the extensive social capital of faith and other communities will result in greater progress in reaching the goal of HIV epidemic control.

FBOs seeking to improve the lives of their congregants and others in their communities have expressed renewed interest in addressing the epidemics of HIV and sexual violence in their communities. On World AIDS Day 2018, PEPFAR formalized and launched the Faith and Community Initiative (FCI) to enhance PEPFAR's engagement with FBOs and other traditional community structures. Ten high-burden countries were selected to receive funding for COP19, and programming to facilitate partnership with FBOs and other traditional community organizations in these countries was developed. In 2019, FCI technical assistance visits were conducted in nine of the 10 countries by S/GAC and field staff; engagement with the field teams helped the FCI cohere around two overarching priorities: to help find men and children living with HIV and bring them into care, and to prevent sexual violence among children and accelerate justice for children who have suffered from it.

At this juncture of the epidemic, when finding the healthy client is particularly critical to epidemic control, PEPFAR must seek to expand our outreach to all partners who can help in this endeavor, including FBO partners, faith-based health providers, faith communities,
and traditional partners, with the aim of leveraging their influence and compassion for impact. PEPFAR aims to identify more people at risk, with the aim of supporting the following goals:

- Increasing community awareness: advances in HIV care, PLHIV viral suppression, and the client’s ability to thrive while preventing transmission of the virus

- Direct engagement with mothers within relevant communities, including communities of faith: early childhood or adolescent testing and treatment, and to provide direct support to children

- Identifying and reaching men at increased risk for HIV and inviting them for HIV testing, including self-testing, and linking and retaining those who test positive in treatment

- Finding children and adolescents with HIV and linking and retaining them in treatment, with particular attention to family index testing and to the challenges for adherence

- Educating PLHIV about TB, and finding those with TB symptoms and referring them to appropriate diagnosis and care

- Addressing stigma and discrimination for both TB and HIV

- Preventing and responding to sexual violence among children

- Supporting DREAMS and OVC programming

**Locally Based Partners**

As part of the planning process, PEPFAR recognized that to sustain epidemic control, it is critical that the full range of HIV prevention and treatment services are owned and operated by local institutions, governments, and community-based and led organizations. In addition, PEPFAR outlined our intent to establish sufficient capacity, capability, and durability of local
partners to ensure successful, long-term, local partner engagement and impact. PEPFAR outlined a goal to transition 70 percent of each implementing agency’s partner load to local partners by the end of COP20 implementation, with an intermediate goal of 25 percent by the end of COP18 and 40 percent by the end of COP19. Each PEPFAR country is expected to contribute to this goal based on the context of the local partner mix and types of public and private partners available to provide essential services. Every country is not expected to reach the 25, 40, and 70 percent benchmarks, but is responsible for pushing for an increased proportion of local partners depending on the country’s context.

Figure 20 illustrates PEPFAR’s progress toward the COP19 benchmark of 25 percent local partners by implementing agencies.

**United States Minority Serving Institutions**

PEPFAR continues to maintain our longstanding partnership with Historically Black Colleges and Universities (HBCUs) through in-country COP-supported programming. In the past, PEPFAR, through the Department of Defense (DoD), worked with Charles R. Drew University of Medicine and Science in Angola and Rwanda. Similarly, through

---

**Figure 20: 2019 COP Funding Allocation by Agency and Operating Unit**

<table>
<thead>
<tr>
<th>USAID Local vs International Partners COP19</th>
<th>HHS/CDC Local vs International Partners COP19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zimbabwe</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Zambia</td>
<td>Zambia</td>
</tr>
<tr>
<td>Vietnam</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Ukraine</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Uganda</td>
<td>Uganda</td>
</tr>
<tr>
<td>Tanzania</td>
<td>Tanzania</td>
</tr>
<tr>
<td>South Sudan</td>
<td>South Sudan</td>
</tr>
<tr>
<td>South Africa</td>
<td>South Africa</td>
</tr>
<tr>
<td>Rwanda</td>
<td>Rwanda</td>
</tr>
<tr>
<td>Nigeria</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Namibia</td>
<td>Namibia</td>
</tr>
<tr>
<td>Mozambique</td>
<td>Mozambique</td>
</tr>
<tr>
<td>Malawi</td>
<td>Malawi</td>
</tr>
<tr>
<td>Lesotho</td>
<td>Lesotho</td>
</tr>
<tr>
<td>Kenya</td>
<td>Kenya</td>
</tr>
<tr>
<td>Haiti</td>
<td>Haiti</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>Ethiopia</td>
</tr>
<tr>
<td>Eswatini</td>
<td>Eswatini</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>Democratic Republic of the Congo</td>
</tr>
<tr>
<td>Cote d’Ivoire</td>
<td>Cote d’Ivoire</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Cameroon</td>
</tr>
<tr>
<td>Burundi</td>
<td>Burundi</td>
</tr>
<tr>
<td>Botswana</td>
<td>Botswana</td>
</tr>
<tr>
<td>Angola</td>
<td>Angola</td>
</tr>
</tbody>
</table>

Local | International
the CDC, PEPFAR funded Howard University to conduct programming in Malawi and South Africa and currently funds fellowship programs through Morehouse School of Medicine. In 2018, eight emerging leaders fellows from HBCUs were supported to conduct work at the CDC in Atlanta, Georgia.

In 2017, PEPFAR supported the HBCUs of Charles R. Drew University of Medicine and Science, Meharry Medical College, Morehouse School of Medicine, and Howard University College of Medicine and their African-based Level 1 hospitals in the creation of an HBCU Global Health Consortium. The Consortium initially worked with four hospitals and their affiliated clinics to transform clinical HIV practice to provide high-quality, comprehensive, and professional care and treatment to PLHIV in Lusaka, Zambia. Following successful implementation, PEPFAR has expanded the partnership to additional sites in FY 2020 and 2021 and introduced a new community health care worker (CHW) certification program to be developed with partners in Malawi.

The Zambia-based project is designed to support HCWs within high-burden HIV settings to address barriers to care and maximize the delivery of HIV services to improve health outcomes along the HIV care continuum. The project launched in February 2017 in Zambia is currently working with four high-volume Lusaka-based hospitals providing HIV services. The Consortium has achieved a high level of impact to date.

- Established a site for adolescent girls that provides a wide range of services to girls with HIV to ensure they are linked to services, retained in care, and receive other support services to enhance their quality of life. The adolescent center also works with a broader group of adolescent girls providing HIV prevention activities. The Consortium’s center collaborates with local DREAMS implementing partners and also participates on the AGYM Technical Working Group.

- Implemented a model for differentiated service delivery that has dramatically decongested the hospital and decreased the waiting time for stable HIV clients to access services. Clients who used to have to wait hours to see a provider at the hospital, requiring time away from work or school, now have little to no waiting time.

- More efficient processes have been put in place for early infant diagnosis, ensuring infants are routinely tested and the results shared and documented within a new electronic medical record system.

- The capacity of data management teams has been improved, allowing hospital staff access to real-time HIV data, which enable them to quickly provide appropriate care to clients. Hospital management also uses these data to ensure that the hospital is nimble in responding to overall needs.

- Supported hospital staff and management to reconfigure the flow of HIV services using the Kaizen model to enhance the efficiency with which patients are served.

In 2019, PEPFAR expanded our HBCU Global Health Consortium work to scale its projects for impact, sharing best practices across sites so that all may benefit from HBCUs’ expertise. In addition to scaling programs in Zambia, PEPFAR is working to establish a CHW training program, whereby successes of HBCUs’ domestic CHW work are transferred to schools in Malawi, allowing high school students to receive CHW certification upon graduation.
Additionally, the PEPFAR Scientific Advisory Board (SAB) includes experts affiliated with HBCUs, such as Celia Maxwell of Howard University and Lejeune Lockett of Charles Drew University of Medicine and Science, and the faith community, such as Reverend Edwin Sanders of the Metropolitan Interdenominational Church of Nashville and Nyambura Njoroge of the World Council of Churches.

**Engaging International and Nongovernment Partners**

**Coordination with Multilaterals**

PEPFAR places great value on engagement with multilateral institutions to ensure that through the collective actions of member states we can achieve maximum efficiency of our resources and maximum impact in our response to the global HIV/AIDS epidemic.

**Global Fund**

The Global Fund is a multilateral financing mechanism that relies on public and private contributions on a three-year replenishment cycle. The Global Fund is a partnership between donor countries, the private sector and private foundations, implementing governments, civil society, international organizations, and affected communities. This partnership governs, oversees, and implements the Global Fund strategic vision of ending HIV/AIDS, TB, and malaria while building resilient and sustainable systems for health, inherently strengthening country capacity to detect and respond to acute outbreaks and disease threats. Programs delivered with Global Fund dollars thereby contribute to enhancing global health security and protecting America’s borders.

The U.S. has been a leader in financial and policy contributions to the Global Fund since the Global Fund’s inception in 2002, and is its largest single donor and technical resource for supporting program delivery at the country level. The U.S. is a permanent member of the Global Fund Board of Directors and currently has a formal role on each of the three board subcommittees.
The U.S. investment in the Global Fund bolsters U.S. bilateral program results including that of PEPFAR, the President’s Malaria Initiative (PMI), and U.S. efforts to combat TB globally; expands the geographic reach of the U.S. global health response and investment; promotes sustainable country-owned responses to the three diseases; and attracts continued investments from other donors to the Global Fund. Since the beginning of our global response to the three diseases, it has been evident that no one country nor institution can accomplish the mission of controlling HIV, malaria, and TB alone. This can only be achieved through the complementary goals set by the leading institutions in the global health space, including PEPFAR, PMI, UNAIDS, WHO, Malaria No More, the Stop TB Partnership, and the Global Fund.

As a financing institution, the Global Fund’s operational model does not include an in-country presence. PEPFAR’s bilateral programming is a strong partner to the Global Fund, providing in-country information and advice. The Global Fund Secretariat sees PEPFAR and PMI as essential contributors to shaping the content of in-country grants. The same approach with the Secretariat is fostered in USAID TB programming.

**UNAIDS**

UNAIDS is a critical leader in driving a comprehensive international response to fight HIV/AIDS. UNAIDS is a unique and innovative partnership of 11 U.N. agencies that draws on the comparative advantages of each for coordinated and targeted action to specific challenges of the HIV/AIDS epidemic.

The U.S. plays a critical and active role in the governance and oversight of UNAIDS through its participation as a member state in the biannual UNAIDS Programme Coordinating Board (PCB) meetings and serves as the board’s chair in 2020. In this forum, the U.S. promotes evidence-based policies and strategies that ensure an effective global response to HIV/AIDS, including...
the provision of comprehensive HIV prevention, care, and treatment services that are free from stigma and discrimination. The U.S. places a special emphasis on women- and girl-centered approaches, country ownership, accountability, and the smarter use of resources for an effective and synergistic global HIV/AIDS response.

UNAIDS’ policy framework and the political commitment to eradicate HIV/AIDS complements and enables PEPFAR and programmatic efforts of the Global Fund. Through PEPFAR, the U.S. government supports and advances the UNAIDS 90–90–90 goals: 90 percent of people with HIV diagnosed, 90 percent of those diagnosed on ART, and 90 percent of those on ART virally suppressed by 2020.

PEPFAR prioritizes working with and through others to build political will, particularly for much needed policies that will help control the pandemic and sustain our joint impact on treatment and prevention, establish international norms, and ensure a broad-based multisector response to enhance and support service delivery.

UNAIDS advocacy and policy support serves a critical role helping countries to plan for and provide their own resources toward sustainability in the HIV response. This effort has resulted in 11 countries funding 50 percent of their own national HIV/AIDS responses, getting us closer to the goal of sustainability and country-led responses.

UNAIDS also serves as an invaluable resource for HIV data, including for PEPFAR programming. UNAIDS works with countries on results monitoring and reporting to help track progress on defined milestones and targets, informing priorities and supporting data-driven and targeted implementation of programs.

The WHO is the normative body for developing guidelines for HIV prevention and treatment, and UNAIDS is a key partner in operationalizing these guidelines by helping countries adopt them into their own HIV programs. WHO guidelines underlie PEPFAR’s COPs as they relate to testing, treatment, and retention targets.

As highlighted, UNAIDS, with its in-country presence and focus, supports effective implementation of PEPFAR funding, Global Fund grants, and other country-level initiatives. Additional UNAIDS efforts that support the broader HIV response include (but are not limited to) the following:

- The global Fast-Track Cities initiative to provide essential technical support over a three-year period to a select number of priority high-burden cities in order to accelerate their HIV responses
- Strengthening FBO leadership and advocacy for Fast-Track Cities and the goal of ending AIDS by 2030, and increasing capacities for scaled up engagement of FBOs in HIV-related testing, prevention, treatment, care, and reduced stigma and discrimination in their respective communities and health care settings; and leading the Champions for an AIDS-Free Generation initiative, a distinguished group of former presidents and influential African leaders committed to the goal of achieving an AIDS-free generation in Africa

**Targeted Private Sector Engagement for Impact**

Partnerships are the cornerstone of PEPFAR’s success. All sectors must work together – on financing, on demonstrating advocacy and political will, on delivering essential services – to end HIV.

Partnerships with the private sector play a critical role in ending the HIV/AIDS response. The private sector can play a crucial role in supporting the response by providing essential services, funding, and technical expertise. Through partnerships, the private sector can leverage its resources and expertise to support the delivery of HIV/AIDS services. The Global Fund’s Private Sector Engagement Framework provides a roadmap for such partnerships.

The framework sets out the following key principles for private sector engagement:

- **Inclusion and Diversity:** Engage a diverse range of private sector partners, including large multinational corporations, small and medium enterprises, and local businesses.
- **Equity and Human Rights:** Ensure that private sector engagement respects human rights, promotes gender equality, and reduces stigma and discrimination.
- **Sustainability and Long-Term Commitment:** Advocate for long-term commitments and sustainability, ensuring that investments are not short-term and that the sector continues to support the response.
- **Innovation and Impact:** Foster innovation and support the development and scale-up of new technologies and services.
- **Transparency and Accountability:** Promote transparency in partnerships, ensuring that agreements are fair and that accountability mechanisms are in place.

By aligning with these principles, the private sector can make a significant contribution to the global response to HIV/AIDS, supporting the achievement of the UNAIDS 90–90–90 targets and the goal of ending the AIDS epidemic by 2030.
Outreach to young men is a critical strategy for PEPFAR. Photo courtesy of PEPFAR Kenya

epidemic, and PEPFAR strategically focuses our PPPs on increasing programmatic impact and efficiency. PEPFAR’s PPP strategy includes finding opportunities where the private sector can complement PEPFAR goals and priorities by leveraging private sector approaches, distribution networks, marketing expertise, innovation, and technology to help achieve epidemic control.

Much like the private sector, PEPFAR is focused on accountability and scale. PEPFAR often looks to business models of private sector companies for ideas on how to most effectively and efficiently implement our programs. PPPs enable PEPFAR not only to share risks, resources, and rewards, but also to find greater efficiencies in program delivery.

In 2019, PEPFAR developed, implemented, and sustained several global PPPs. In addition to finding efficiencies within the program, these partnerships demonstrate PEPFAR’s continued commitment to achieving epidemic control among children, AGYW, and men. Some of these partnerships are highlighted in the following sections.

Engaging Men in New and Innovative Ways to Break the Cycle of Infection

MenStar Coalition

The MenStar Coalition, launched in 2018, is a global PPP designed to reach an additional 1 million men with HIV treatment and support more than 90 percent of men to be virally suppressed, in order to effectively interrupt HIV transmission.

The MenStar Coalition brings together the HIV service delivery capacities of the public sector with the consumer-oriented marketing acumen of the private sector to optimize efforts to reach men with HIV testing and treatment services. The MenStar Coalition takes a coordinated, client-centered approach to identify insights and underlying barriers to men testing, linkage to HIV treatment, and achievement of viral suppression. Powered by these insights, the MenStar Coalition has developed and refined innovative demand creation and supply side strategies to engage men and differentiate treatment services for men.

MenStar’s goals are being achieved through multiple approaches: quantitative and qualitative research to better understand and adapt services to men’s needs, targeted demand creation using
consumer marketing approaches, innovations such as HIV self-testing, and improvements to the service delivery experience. To further improve initiation and retention in HIV treatment programs, PEPFAR has recommended strengthening the service delivery experience to be more convenient and welcoming to men, through interventions such as shorter wait times; fewer appointments; extended hours; male-only spaces; enhanced focus on confidentiality; and empathetic, well-trained, well-supported providers.

Furthermore, the partnership is applying insights gleaned from the private sector on how to communicate to men the functional and emotional benefits of this new health care model, as well as the availability of better performing drugs. The partnership is using the private sector insights to develop a rebranding campaign to communicate with men in a way that demonstrates understanding of their needs. The partnership will also ensure essential HIV commodities and services are available to meet increased consumer demand.

Delivering for Adolescent Girls and Young Women

*DREAMS: Determined, Resilient, Empowered, AIDS-Free, Mentored, and Safe: a Public–Private Partnership*

Through collaboration with the private sector, PEPFAR is leading the ambitious DREAMS Partnership to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women with the goal of reducing new HIV infections among AGYW in the highest HIV-burdened geographic areas of 15 countries. The multisectoral DREAMS interventions go beyond the health sector to address the structural drivers that directly and indirectly increase girls' HIV risk, including poverty, gender inequality, sexual violence, and a lack of education.

As of 2019, new HIV diagnoses among AGYW have declined by 25 percent or greater in nearly all of the regions implementing DREAMS across 10 high-burden African countries.

*Private Sector Engagement*

Private sector and philanthropic partners remain central to the success of DREAMS by contributing their unique expertise and capabilities to strengthen and complement DREAMS programming.
The Gates Foundation is conducting an impact evaluation and implementation science research to measure the results of DREAMS and the difference it is making in the lives of AGYW. Girl Effect is leveraging its expertise in brand creation, media, and communications to develop a youth brand that is reaching Malawian youth with key messages on gender norms, equality, and friendship between girls and boys. Gilead Sciences continues to provide generic PrEP drugs to meet the rising demand among AGYW in DREAMS districts. Johnson & Johnson is supporting the development of DREAMS Ambassadors and amplifying the voices of AGYW through support of a peer-to-peer model program, and has conducted market segmentation analytics to better understand the behaviors of AGYW to support programmatic design that is responsive to the most urgent needs of AGYW. Lastly, ViiV Healthcare has been instrumental in building the capacity of CBOs working on AGYW programming.

In order to infuse innovative solutions, support indigenous and community-based organizations, and complement the DREAMS core package of interventions, PEPFAR launched the DREAMS Innovation Challenge in 2016. The Innovation Challenge had six focus areas: strengthening the capacity of communities for service delivery, keeping girls in secondary school, linking men to services, supporting PrEP, providing a bridge to employment, and applying data to increase impact. Fifty-five organizations were selected to implement innovative solutions found through the Challenge that built upon existing approaches and furthered the DREAMS’ commitment to reducing HIV infections among AGYW.

Of the organizations selected for the Challenge, nearly 40 percent had never received PEPFAR funding and nearly two-thirds were small CBOs. Examples of solutions that were implemented through the DREAMS Innovation Challenge include: combining PrEP services to AGYW with the distribution of self-testing kits to their male partners; instituting an early warning system to improve girls’ retention in secondary school; training AGYW in skills linked to employment such as mechanics, financial literacy, and coding; use of community libraries as safe spaces to provide
mentorship and information on HIV prevention; and the use of celebrities and musicians to create demand for prevention and PrEP services.

Over the course of two years, grantees through the Innovation Challenge successfully reached the following:

- 144,479 AGYW with HIV education, awareness, and prevention services through community strengthening
- 103,045 AGYW with interventions to keep them in school
- 9,742 AGYW with PrEP enrollment through increased demand creation activities
- 31,070 AGYW with workforce development trainings, of which 16,813 have been placed in jobs

More than half of the Innovation Challenge implementing organizations have secured additional funding to sustain their programs beyond the two-year period of the Innovation Challenge, with 50 percent classified as indigenous organizations across the 10 DREAMS countries. Furthermore, a central component of the Challenge was building the organizational capacity of grantees to strengthen their implementation abilities and help them be successful. At the completion of the Challenge, of the grantees that completed an organizational capacity assessment, 80 percent showed improvement in at least one of the six domains assessed.

The Innovation Challenge was able to support new, innovative solutions to addressing the complex needs of AGYW and also strengthened the ability of indigenous and community-based organizations to effectively deliver HIV/AIDS services to AGYW.

**Go Further Partnership**

Cervical cancer is the number one cancer killer of women in sub-Saharan Africa. An estimated 100,000 women in sub-Saharan Africa are diagnosed annually with cervical cancer and of these about 62 percent will die from the disease. WLHIV are up to five times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive forms and with higher mortality. Cervical cancer is preventable through HPV immunization prior to HPV infection and screening and treatment of precancerous lesions. Cervical cancer screening of WLHIV should be a routine element of HIV care in sub-Saharan Africa in high HIV-1/HPV co-infection areas to prevent mortality from this infection.

In 2018, PEPFAR announced a bold shift in our programming for cervical cancer screening and treatment. Given the high rates of mortality among WLHIV due to cervical cancer, PEPFAR developed an age-band appropriate, comprehensive strategy to reduce cervical cancer risk by 95 percent in WLHIV by every-other-year cervical cancer screening for WLHIV over age 25. This strategy creates a pathway to ending cervical cancer in WLHIV in sub-Saharan Africa.

Go Further is an innovative PPP between PEPFAR, the Bush Institute, UNAIDS, and Merck. For maximum impact, Go Further focuses on reaching WLHIV in countries with among the highest HIV prevalence and cervical cancer incidence rates in the world. The partnership aims to reduce new cervical cancer cases by 95 percent among the estimated 3.8 million WLHIV who live in eight original target high-burden African countries: Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe. In 2020, four additional African countries with large populations of WLHIV were added to the partnership. The Go Further strategy builds on seven years of collaboration between PEPFAR and the Bush Institute and evolves the partnership to save more lives.
On the margins of the 2019 United Nations General Assembly, former President George W. Bush and Ambassador Deborah L. Birx announced that the Go Further partnership had reached more than a half-million WLHIV with cervical cancer screening and treated thousands of women for preinvasive cancerous lesions in its first year. The number of women screened should surpass 1 million during FY 2020.

**Optimizing Access to HIV Diagnosis in Children**

*Partnering to Save Children*

Children under age 15 have inadequate access to HIV diagnosis and treatment; while there has been a dramatic decline in new pediatric infections, there are still millions of children who are in critical need of lifesaving treatment. The global community has made great progress in improving access to HIV testing and treatment services for adults; however, more than 110,000 children continue to die each year from AIDS-related causes and more than 15,000 children are newly infected each month. Without lifesaving ART for children living with HIV, 50 percent will die by their second birthday and 80 percent will die by their fifth birthday.

To address this challenge, PEPFAR joined the Holy See and UNAIDS to convene a series of High-Level Dialogues with leaders of major diagnostic and pharmaceutical companies, multilateral organizations, governments, regulators, FBOs, and others who are directly engaged in providing services to children and adolescents living with and vulnerable to HIV. During these dialogues, key stakeholders agreed to specific good-faith commitments to focus, accelerate, and collaborate on the development, registration, introduction, and rollout of the most optimal pediatric formulations and diagnostics. PEPFAR recognized the need to facilitate and expedite the research, development, approval, introduction, and uptake of optimal drugs and formulations for infants, children, and adolescents.

The generous support from pharmaceutical and diagnostic manufacturers is critical to expanding access to lifesaving HIV therapy for children in the developing world.
Specifically, these companies committed to developing and gaining regulatory approval for specific lifesaving drugs and diagnostic tools, including distributing pediatric formulations in select countries. These efforts will be instrumental toward the goal of reducing new HIV infections to under 20,000 children by 2020, as called for by the Super Fast-Track Targets.

As of September 30, 2019, PEPFAR has supported lifesaving ART for nearly 700,000 children.

Dedication from all sectors – governments, donors, private sector, pharmaceutical, and faith-based and community partners – is critically important for the PEPFAR program to succeed in reaching children in need with safe, effective, and affordable HIV testing and treatment before they get sick.

**Finding Efficiencies in PEPFAR Programs**

**Labs for Life and Infection Prevention and Control PPP**

PEPFAR, the CDC, and Becton Dickinson (BD) have a longstanding PPP (Labs for Life) focused on laboratory systems strengthening toward achieving the UNAIDS 90-90-90 targets. Through activities such as continuous quality improvement (CQI), accreditation to International Organization for Standardization (ISO) 15189 standards, and implementation of efficient sample referral networks, the partnership has demonstrated continued success and progress toward sustainable, quality assured, and timely HIV diagnosis and treatment monitoring services for PLHIV in high-burden countries.

Now in its third phase, the partnership is being implemented in Rwanda, Haiti, Ethiopia, India, Kenya, and Uganda and is focused on providing continuous quality improvement, laboratory human resources strengthening, TB prevention, and specimen referral system strengthening. In the current phase, the partnership is working in 38 laboratories, and to date, 41 BD fellows have been deployed in-country and 20 mentorship rounds have been conducted, resulting in significantly improved laboratory quality assessment scores. In some countries, assessment scores improved by as much as 124 percent and 150 percent.

PEPFAR and BD have also partnered on Infection Prevention and Control in Kenya to improve infection prevention practices, such as safe injection use and handling, that are critical to prevent further transmission of HIV and other blood-borne pathogens to HCWs and patients. The implementation approach includes conducting baseline assessments, quality improvement interventions, and pre- and post-training evaluations across nine facilities in Kenya. The partnership will continue scaling up efforts over the next year to address HIV transmission among HCWs and patients.

**Partnering on Client-Centered Supply Chain Modernization**

PEPFAR is exploring ways to leverage private sector solutions to modernize the supply chain. The private sector can play an important role in delivering a client-centered supply chain that meets clients’ needs. In August 2019, PEPFAR hosted a roundtable discussion to source ideas from private sector supply chain experts and stakeholders on new solutions to reduce inefficiencies and service delivery costs, increase end-to-end visibility, and strengthen the global PEPFAR supply chain. Given private sector expertise in getting products to people as quickly, cost-effectively, and accurately as possible, they may be able to play a role in sourcing, warehousing, logistics, transporting, and final mile delivery. PEPFAR is also learning from industry innovations and techniques to deliver efficiently to patients by using cutting-edge technology and the latest client insights.
Strengthening Health Training and Data Systems

Human Resources for Health (HRH)

HIV treatment coverage is at just over 50 percent globally, requiring already strained health systems to find and care for an increased number of patients to reach country and global targets by 2030. Successful implementation of differentiated care models and scale-up of MMD will enable patients to receive care in ways that better meet their needs, but health facilities and community-based service points will need to see new patients at increasing rates due to innovative case-finding models. Linking and retaining patients on lifelong ART requires investments in critical lay cadres such as expert clients and community health workers.

Current staffing deficits and anticipated need for additional health workers are further informed by the fiscal environments of many countries, where there are constraints on wage bills impacting hiring and filling of health worker vacancies. Successful achievement and maintenance of each of the 90–90–90 targets necessitates that PEPFAR continue to address, in collaboration with countries’ MOH, ministry of public works (or equivalent), MOF, and other stakeholders, the large human resource challenges facing the delivery of HIV services. While countries continue to face significant gaps in the availability of HRH, it is critical that they work to ensure optimal use of available HRH for maximum impact and advancement of client-centered care. This entails consideration for the following:

▶ HRH data use: Have a data-driven approach in determining and monitoring HRH requirements, allocation, performance, and productivity to support HIV target achievement and rollout of key policies such as MMD.

▶ PEPFAR HRH inventories should be used to monitor the allocation, productivity, and impact of PEPFAR-supported HRH by linking changes in cadres to relevant MER indicators.

▶ Human Resource Information Systems (HRIS) or equivalent systems are critical to ensure availability and use of national HRH data. Investments in HRIS result in increased ability of PEPFAR and country governments to utilize HRH data for decision-making at national, subnational, and facility levels. Continued investments in HRIS will include an explanation of how existing efforts are aligned to the WHO minimum data sets for HRH registries and have yielded greater data use that resulted in effective and efficient HRH recruitment, allocation, and retention. At a minimum, HRIS investments should enable tracking HRH down to the facility level. Emphasis should be placed on effective and efficient counseling and case management methods that promote retention and uptake of MMD.

▶ Strengthening efficiency and team-based care: Ensuring that all health workers have regularly communicated clear roles and responsibilities, and that provider workflow and handoff is monitored and realigned for greater efficiency and client-centered care. Efforts should be in place to optimize multidisciplinary team-based approaches for case management to support client-specific needs and retention.

HRH sustainability planning, which is essential for ensuring host-country governments’ ability to support HCWs’ requirements for the provision of HIV services, is necessary for long-term capacity to manage the HIV response. Sustainability planning is particularly
relevant for countries close to achieving epidemic control. All countries should take steps toward HRH sustainability planning, including the following:

- **Alignment of HRH support to host-country government systems** is key for facilitating any planned public sector absorption of workers required for sustained epidemic control. Plans for HRH absorption should be connected to broader domestic resource mobilization efforts to advance greater shared responsibility of HIV services.

- **Review and consideration of how roles/responsibilities of cadres supporting HIV services who are not formally recognized by country can be formally integrated into countries’ health systems**

- **Advance use of private sector workforce through further introduction of market-based solutions and decentralization of HIV services to expand access to client-centered HIV services**

- **Countries nearing epidemic control should conduct a more rigorous analysis of workforce requirements to support essential “maintenance package” of HIV services to inform concise and up-to-date planning.**

Country governments’ ability to support health workers required for the provision of HIV services is necessary for long-term capacity to manage the HIV response. Alignment of HRH support to host-country government systems is key for facilitating absorption of workers required for sustained epidemic control. Data systems such as HRIS are critical for allocation and monitoring of HRH for achieving sustainable epidemic control. Routine optimization of PEPFAR-supported HRH for maximum impact is undertaken using the HRH inventories. To advance integrated patient-centered care, HRH staffing will be configured toward team-based care and case management.
Evaluation Standards of Practice

Background

In January 2014, PEPFAR issued the inaugural version of the PEPFAR Evaluation Standards of Practice (ESoP), outlining the 11 standards of practice that should be followed to ensure high standards of evaluation planning, implementation, dissemination, and use. Subsequent releases of the ESoP – including the most recent, ESoP 3.1 – have maintained the original 11 standards, refined PEPFAR evaluation classification, and provided updated guidance on reporting requirements and processes. The ESoP set key parameters that inform PEPFAR evaluation quality assurance and reinforce the importance of using evaluation findings in programmatic decision-making. All PEPFAR evaluations, regardless of the implementing agency, partner, or type of evaluation, must adhere to these standards.

PEPFAR defines evaluation as the “systematic collection and analysis of information about the characteristics and outcomes of the program, including projects conducted under such program, as a basis for making judgments and evaluations regarding the program, improving program effectiveness, and informing decisions about current and future programming.”

Evaluation definitions, classifications, timeframes, example questions, data sources, and indicators can be found in ESoP 3.1.

Between FY 2017 and FY 2019, PEPFAR-funded countries reported on process, outcome, impact, and economic evaluations, as in previous years, but also on implementation science (IS) and operations research (OR) activities. The primary update between ESoP 3.0 and ESoP 3.1 was the reclassification of IS and OR from evaluation to research. Beginning in FY 2020, new IS and OR will no longer be captured in the ESoP modules of PEPFAR’s Data for Accountability, Transparency and Impact Monitoring (DATIM) system.

---

7 PEPFAR classifies evaluation into four types: process, outcome, economic, and impact. However, in the context of PEPFAR, impact evaluations are often not practical – operationally, financially, or ethically – since they require a counterfactual. Additionally, other programmatic changes or guidance that may affect the usefulness of the results of impact evaluations have often been implemented in the meantime. PEPFAR uses routine granular site-level age/sex data to determine interventions’ effectiveness and make real-time changes, and has robust longitudinal data by site and age/sex that support the use of these data for program evaluation.
The PEPFAR Standards of Practice (SoP)

The Adherence Checklist, the tool that assesses completed evaluations against the standards, must be completed for all evaluations. The 11 standards are listed below, and full descriptions can be found in ESoP 3.1.

1. Engage stakeholders.
2. Clearly state evaluation questions, purpose, and objectives.
3. Use appropriate evaluation design, methods, and analytical techniques.
4. Address ethical considerations and assurances.
5. Identify resources and articulate budget.
6. Construct data collection and management plans.
7. Ensure appropriate evaluator qualifications and independence.
8. Monitor the planning and implementation of evaluations.
9. Produce quality evaluation reports.
10. Disseminate results.
11. Use findings for program improvement.

Methods

This report includes a presentation of overall findings from evaluation, IS, and OR submissions in DATIM for FY 2019. FY 2019 is the sixth year for submission of evaluation results. Some evaluations started in years prior to the release of the ESoP in 2014, and as such, some flexibility was allowed for evaluations that began before the release of the standards. Agencies reviewed, verified, and assessed the evaluation, IS, and OR data submitted for PEPFAR’s 2020 Annual Progress Report process, each using an agency-specific process. Results from the agencies were aggregated for this report.

Determining adherence to the standards is dependent on a review of a final evaluation report, with the use of the Adherence Checklist to answer a series of review criteria associated with each standard. Responses to these criteria include: Yes, Partial, and No. For composite standards based on several questions, if all answers were “yes,” the final score was “yes”; if all were “no,” the final score was “no”; and any other combination of answers was given a “partial” score. The data presented were verified to assess completeness and confirmed to be completed during the reporting period, and meet the PEPFAR ESoP definitions of evaluation, IS, or OR activities.

Findings

Overall, a total of 104 evaluation, IS, and OR submissions were reported in FY 2019. Of these reported evaluation, IS, and OR activities, 38 were completed in FY 2019. In FY 2018, there were a total of 68 completed evaluation, IS, and OR activities reported in the Annual Report to Congress; there were a total of 92 completed evaluations reported in FY 2017.USAID reported a total of 38 activities, of which 18 were completed evaluation, IS, and OR activities, and the remainder were in planning and implementation stages. The 18 completed evaluations represent activities in 14 PEPFAR countries, including three in Namibia, two in South Africa, two in Côte d’Ivoire, and one each in 11 other countries or regions. The 18 completed activities represent process evaluations (1), outcome evaluations (3), impact evaluations (1), economic evaluations (4), implementation science (3), operations research (3), and other (3), as seen in Table 1.

Due to the extensive data cleaning and verification process that occurs after the annual reporting deadline (Nov. 15), the actual number of completed evaluations and reporting of the standards based on the submitted Adherence Checklist presented in this report may change. For example, after data cleaning occurred and evaluations underwent a de-duplication process, the updated number of completed FY 2018 evaluations are 68 (CDC reported four fewer and DoD reported one fewer) and the updated number of completed FY 2017 evaluations are 92 (CDC reported five fewer and USAID reported 12 fewer).
The CDC reported a total of 57 activities, of which 20 were completed evaluations and the remainder were in planning and implementation stages. The 20 completed evaluations represent activities in 15 PEPFAR countries, including four in Zimbabwe, two in South Africa, two in Kenya, and one each in 12 other countries or regions. The 20 completed activities represent process evaluations (5), outcome evaluations (14), and economic evaluations (1), as seen in Table 1.

DoD reported nine evaluation and OR submissions during FY 2019. DoD did not report any completed evaluations; five evaluations were in the implementation stage.

PEPFAR legislation requires reporting on the number of completed evaluations within the fiscal year that are publicly disseminated. (Note that this is separate from SoP 10, which relates to public dissemination within 90 days of completion.) At the time of this report, 100 percent of FY 2019 evaluation, IS, and OR activities have been publicly disseminated, which is an increase from the 79 percent disseminated in FY 2018. PEPFAR recognizes the importance of dissemination of findings, as it helps ensure that results are used in a timely manner to make critical decisions. PEPFAR and our implementing agencies will continue to make efforts to ensure stakeholders are aware of the importance of the requirement to disseminate results.

### Adherence to Standards

FY 2019 evaluations were found to have high adherence to eight of the 11 SoPs, moderate adherence to one standard, and low adherence to two standards.

Adherence changed across several standards between FY 2018 and FY 2019 (Figure 21). Most aggregate scores remained within the same category of high, moderate, or low, with the exception of two that increased from low to moderate:

- SoP 1 (stakeholder engagement) improved from 75 percent to 84 percent
- SoP 2 (evaluation purpose) decreased from 99 percent to 95 percent

---

9 The number of evaluation activities contributing to the calculated adherence statistic was 68 in FY 2018 and 38 in FY 2019. FY 2018 adherence rates are updated from the evaluation activities reported in the FY 2018 Annual Report to Congress.
‣ SoP 3 (appropriate evaluation design, methods, and analytical techniques) decreased from 97 percent to 92 percent

‣ SoP 4 (ethical considerations) decreased from 87 percent to 76 percent

‣ SoP 5 (articulate budget) improved from 12 percent to 18 percent

‣ SoP 6 (data collection and management) decreased from 90 percent to 84 percent

‣ SoP 7 (ensuring appropriate evaluator competencies and qualifications) improved from 51 percent to 61 percent

‣ SoP 8 (monitoring implementation) improved from 37 percent to 45 percent

‣ SoP 9 (produce quality reports) decreased from 79 percent to 71 percent

‣ SoP 10 (dissemination) decreased from 15 percent to 13 percent

‣ SoP 11 (use of findings) decreased from 88 percent to 82 percent
Table 2 shows that agencies reported the lowest adherence to SoP 5 and SoP 10 and moderate adherence to SoP 8. Justifications for low scores are provided by agencies as follows.

**USAID Adherence to Standards**

USAID’s level of adherence to SoP 5 (Identify Resources and Articulate Budget) and SoP 10 (Disseminate Results) remains low (Table 2.1).

Within USAID, IS and OR studies are governed by the agency’s scientific research policy. This policy differs from the evaluation policy and affects both how these studies are implemented and how their results are disseminated (i.e., via published manuscripts rather than evaluation reports). Ultimately, this affects how well IS and OR typically meet standards PEPFAR outlined for evaluations (ESoP) and is one of the prominent reasons for lower adherence with certain standards such as SoP 5 and SoP 10. Moreover, the low score on SoP 5 is also due to evaluation budget and/or cost traditionally not being reported in published manuscripts or publicly available reports. Economic evaluations also appear to currently fall short on meeting these two standards in full. Standard dissemination formats used for economic evaluations, most of which are cost analyses, typically do not include all the information required by these standards. This appears to be another factor contributing to lower scores in these two areas. Nevertheless, in the case of all study types, USAID collects and reports this information via DATIM for internal PEPFAR use.
Low adherence to SoP 10 represents a combination of factors that this composite measure tracks. One of the most substantial challenges, however, relates to the requirement that results be made public within 90 days from the study completion. While great effort has been made to enhance the use of relevant data and results to guide PEPFAR program decisions throughout the life of each study, meeting the prescribed timeline for public release of the results has been more challenging. This is mainly due to the scientific review process and related scientific journal embargo periods, but also due to delays in receiving formal approvals for evaluation reports by USAID country teams, who put significant effort into ensuring the quality and completeness of all reports.

### Table 2: FY 2019 Adherence to Standards, N=38

<table>
<thead>
<tr>
<th>Scores</th>
<th>SoP 1</th>
<th>SoP 2</th>
<th>SoP 3</th>
<th>SoP 4</th>
<th>SoP 5</th>
<th>SoP 6</th>
<th>SoP 7</th>
<th>SoP 8</th>
<th>SoP 9</th>
<th>SoP 10</th>
<th>SoP 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>32</td>
<td>36</td>
<td>35</td>
<td>29</td>
<td>7</td>
<td>32</td>
<td>23</td>
<td>17</td>
<td>27</td>
<td>5</td>
<td>31</td>
</tr>
<tr>
<td>Partial</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>6</td>
<td>0</td>
<td>5</td>
<td>11</td>
<td>2</td>
<td>10</td>
<td>30</td>
<td>4</td>
</tr>
<tr>
<td>No</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>3</td>
<td>31</td>
<td>1</td>
<td>4</td>
<td>19</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>% of Adherence</td>
<td>84%</td>
<td>95%</td>
<td>92%</td>
<td>76%</td>
<td>18%</td>
<td>84%</td>
<td>61%</td>
<td>45%</td>
<td>71%</td>
<td>13%</td>
<td>82%</td>
</tr>
</tbody>
</table>

*Green - high (61% or greater)  Orange - moderate (41 – 60%)  Red - low (40% or less)*

### Table 2.1: FY 2019 Adherence to Standards – USAID, N=18

<table>
<thead>
<tr>
<th>Scores</th>
<th>SoP 1</th>
<th>SoP 2</th>
<th>SoP 3</th>
<th>SoP 4</th>
<th>SoP 5</th>
<th>SoP 6</th>
<th>SoP 7</th>
<th>SoP 8</th>
<th>SoP 9</th>
<th>SoP 10</th>
<th>SoP 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>16</td>
<td>18</td>
<td>16</td>
<td>14</td>
<td>7</td>
<td>16</td>
<td>9</td>
<td>17</td>
<td>8</td>
<td>5</td>
<td>15</td>
</tr>
<tr>
<td>Partial</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>6</td>
<td>1</td>
<td>10</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>11</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>% of Adherence</td>
<td>89%</td>
<td>100%</td>
<td>89%</td>
<td>78%</td>
<td>39%</td>
<td>89%</td>
<td>50%</td>
<td>94%</td>
<td>44%</td>
<td>28%</td>
<td>83%</td>
</tr>
</tbody>
</table>

*Green - high (61% or greater)  Orange - moderate (41 – 60%)  Red - low (40% or less)*
effort in ensuring that host-country governments and other stakeholders have an opportunity for continued involvement throughout the evaluation process. Further efforts will be made to reduce these delays and make results widely accessible as soon as each study is completed.

Nevertheless, during FY 2019, USAID worked to solidify and enhance the quality of nonroutine data activities and their adherence to the 11 PEPFAR ESoP. As a result, USAID activities exhibit high scores on seven out of 11 standards. Moreover, the score for SoP 7 improved from low in FY 2018 to moderate in FY 2019, with the majority of completed evaluations 85 percent (15) either fully or partially meeting this standard and only three falling short in terms of adhering to the expectation. As for SoP 9, a demanding composite measure, all the studies either partially (10) or fully (8) met the standard. This is a substantial improvement from the year past when almost 50 percent of reported studies failed to adhere to the standard.

**CDC Adherence to Standards**

The CDC reported low adherence to SoP 5 (Identify Resources and Articulate Budget), SoP 8 (Monitor the Planning and Implementation of an Evaluation), and SoP 10 (Disseminate Results) (Table 2.2).

Published manuscripts are the CDC’s primary method for disseminating evaluation results and constitute approximately 95 percent of CDC evaluation reports. The level of adherence to SoP 5 reflects budget and/or cost information not typically being included in published manuscripts. CDC has developed supplementary tools and internal guidance to improve the collection and reporting of evaluation costs. However, it remains a challenge for some CDC country teams to provide budget and/or cost information from specific evaluation studies due to significant staffing rotation within cooperative agreement lifecycles, weak internal tracking systems for evaluations, and supported countries typically conducting evaluations as part of larger cooperative agreements that are not structured to specify evaluation costs. The CDC will continue its efforts to strengthen tracking of evaluation costs.

Similarly, low adherence for SoP 8 is also related to the use of publications as

<table>
<thead>
<tr>
<th>Scores</th>
<th>SoP 1</th>
<th>SoP 2</th>
<th>SoP 3</th>
<th>SoP 4</th>
<th>SoP 5</th>
<th>SoP 6</th>
<th>SoP 7</th>
<th>SoP 8</th>
<th>SoP 9</th>
<th>SoP 10</th>
<th>SoP 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>16</td>
<td>18</td>
<td>19</td>
<td>15</td>
<td>0</td>
<td>16</td>
<td>14</td>
<td>0</td>
<td>19</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>Partial</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>19</td>
<td>2</td>
</tr>
<tr>
<td>No</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>20</td>
<td>1</td>
<td>1</td>
<td>19</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>% of Adherence</td>
<td>80%</td>
<td>90%</td>
<td>95%</td>
<td>75%</td>
<td>0%</td>
<td>80%</td>
<td>70%</td>
<td>0%</td>
<td>95%</td>
<td>0%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Green - high (61% or greater) Orange - moderate (41 - 60%) Red - low (40% or less)
the main source for reporting. Details regarding how an evaluation is planned and implemented are included in all evaluation protocols but are not typically included in publications. While some information about data management and other procedures may have been included, more often there was not enough detail provided to document complete adherence to the standard. The supplementary tools mentioned above will also improve the CDC’s ability to document adherence to SoP 8.

SoP 10 includes two subquestions on (1) inclusion of a dissemination plan and (2) timely uploading of deliverables within 90 days of completion. The CDC has high adherence (100 percent) to articulating dissemination plans in evaluation reports, but tracking the exact timing of public dissemination is a challenge due to the scientific review process and embargo periods enforced by scientific journals.

**Discussion**

PEPFAR will continue to provide technical assistance and support to field teams to improve areas that fall short of high adherence. Additionally, PEPFAR will work closely with headquarters and country teams to improve the quality of evaluations and expand the availability of results. An Evaluation Short Term Task Team was established in FY 2018, and one of the deliverables of this group was to actively analyze gaps to assess (a) how to best fulfill existing policies and requirements and (b) whether any need special consideration or modification. Establishment of the team resulted in the updated version of the PEPFAR ESoP 3.1 and improvements to Adherence Checklist data elements and response fields. ESoP 3.1 aims to better differentiate between different types of nonroutine data activities and address some of the challenges that have led to low adherence. Moreover, the Evaluation Short Term Task Team improved interagency collaboration, a necessity in terms of standardization of evaluation planning, monitoring, implementation, and reporting guidance. PEPFAR continues to explore additional ways to increase engagement of headquarters and country-level staff with evaluators, working to promote these SoPs to all implementing partners to ensure improved adherence.

With the hopes of improving consistent reporting across all agencies, PEPFAR will continue to encourage agencies to develop supplementary tools to improve adherence to SoP 8. Moreover, increased emphasis will be placed on SoP 5 and SoP 10, highlighting the need to improve articulation of budget and public dissemination of reports within 90 days of completion to reach 100 percent. PEPFAR has reviewed agency policies and practices to ensure they are consistent and share the same ultimate objective of public access. This year, PEPFAR will continue to focus our attention on evaluation portfolios that are strategic and well-planned, answer existing evidence gaps, and are linked to country priorities and the greater PEPFAR goal of reaching 95-95-95.
Figures and Tables

**Figure A**: Remarkable Expansion of Prevention and Treatment Services with Flat Budget since 2010 ........................................ 5

**Figure B**: PEPFAR’s Latest Global Results (as of September 30, 2019) .................................................. 5

**Figure C**: PEPFAR-Supported Countries Worldwide ............... 6

**Figure D**: The Pathway to Reaching Epidemic Control (Eswatini) 7

**Figure E**: Changes in Mortality and New HIV Infections in Select PEPFAR-Supported Countries

  Panel A ...................................................... 10
  Panel B ........................................................ 11
  Panel C ................................................................ 12
  Panel D ................................................................ 13

**Figure F**: Progress Toward UNAIDS 90-90-90 Targets Among Those Ages 15 and Older ..................................................... 15

**Figure G**: Progress Toward UNAIDS 90-90-90 Targets Among Those Ages 15-24 .......................................................... 15

**Figure 1**: Patient-Centered Monitoring in PEPFAR .................. 21

**Figure 2**: Progress Toward 95-95-95 Across Select Countries in Southern, East, and West Africa ................................. 22

**Figure 3**: Progress Toward 95-95-95 Among 15-24-Year-Olds Across Select Countries in Southern, East, and West Africa ........................................ 22

**Figure 4**: Progress Toward 95-95-95 Among Adult Men Across Select Countries in Southern, East, and West Africa ........................................... 23

**Figure 5**: Progress Toward 95-95-95 Among Adult Women Across Select Countries in Southern, East, and West Africa ................................. 23

**Figure 6**: Adults and Children Newly Infected with HIV .......... 25

**Figure 7**: Number of AIDS-Related Deaths, Global, 1990-2018 and 2020 Target ......................................................... 25

**Figure 8**: Number of AIDS-Related Deaths, Eastern and Southern Africa and Western and Central Africa, 1990-2018 ....................... 25

**Figure 9**: Number of AIDS-Related Deaths, Regions Outside Sub-Saharan Africa, 1990-2018 ........................................ 25

**Figure 10**: New Infections vs. Total Deaths Among PLHIV in Rwanda ................................................................. 27

**Figure 11**: Changes in New Infections and All-Cause Mortality Among Individuals Ages 15 and Older ................................. 28

**Figure 12**: Changes in New Infections and All-Cause Mortality in Select PEPFAR-Supported Countries ................................. 30

**Figure 13**: Changes in New Infections and All-Cause Mortality in Additional PEPFAR-Supported Countries ......................... 31

**Figure 14**: Changes in New Infections and All-Cause Mortality in Additional PEPFAR-Supported Countries ................................. 32
Figure 15: Changes in New Infections and All-Cause Mortality in Additional PEPFAR-Supported Countries  .......... 33

Figure 16: Trends in Program Growth Compared with Expectations – 2018Q4 to 2019Q3, by Age, Sex, and Country

Panel A ................................................................. 42
Panel B ................................................................. 43
Panel C ................................................................. 44
Panel D ................................................................. 45

Figure 17: FY 2019Q3 Low VL Coverage in the Midst of High Suppression in Some PEPFAR-Supported Countries. .......... 47

Figure 18: Overview of PEPFAR-Recommended Newer Pediatric ARVs/Formulations ................................. 49

Figure 19: DREAMS Core Package  ......................... 62

Figure 20: 2019 COP Funding Allocation by Agency and Operating Unit .................................................. 81

Figure 21: Report Adherence to Evaluation Standards of Practice – FY 2015 to FY 2019

Panel A - SoP 1–6 ......................................................... 97
Panel B - SoP 7–11 ......................................................... 98

Table 1: FY 2019 Completed Evaluations by Agency .................. 96
Table 2: FY 2019 Adherence to Standards, N=38 ....................... 99
Table 2.1: FY 2019 Adherence to Standards – USAID, N=18 ........ 99
Table 2.2: FY 2019 Adherence to Standards – CDC, N=20 ........... 100
## Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Accelerating Children’s HIV/AIDS Treatment Initiative</td>
</tr>
<tr>
<td>AGYW</td>
<td>Adolescent Girls and Young Women</td>
</tr>
<tr>
<td>ANC</td>
<td>Antenatal Care</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral Therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral Medication</td>
</tr>
<tr>
<td>CBO</td>
<td>Community-Based Organization</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>COP</td>
<td>Country Operational Plan</td>
</tr>
<tr>
<td>CSO</td>
<td>Civil Society Organization</td>
</tr>
<tr>
<td>DREAMS</td>
<td>Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe</td>
</tr>
<tr>
<td>DTG</td>
<td>Dolutegravir</td>
</tr>
<tr>
<td>FBO</td>
<td>Faith-Based Organization</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GBV</td>
<td>Gender-Based Violence</td>
</tr>
<tr>
<td>Global Fund</td>
<td>The Global Fund to Fight AIDS, Tuberculosis and Malaria</td>
</tr>
<tr>
<td>HCW</td>
<td>Health Care Worker</td>
</tr>
<tr>
<td>HRH</td>
<td>Human Resources for Health</td>
</tr>
<tr>
<td>HTS</td>
<td>HIV Testing Services</td>
</tr>
<tr>
<td>KP</td>
<td>Key Population</td>
</tr>
<tr>
<td>LGBT</td>
<td>Lesbian Gay Bisexual Transgender</td>
</tr>
<tr>
<td>MER</td>
<td>Monitoring, Evaluation, and Reporting</td>
</tr>
<tr>
<td>MOF</td>
<td>Ministry of Finance</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MSM</td>
<td>Men who have Sex with Men</td>
</tr>
<tr>
<td>OVC</td>
<td>Orphans and Vulnerable Children</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>U.S. President’s Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>PHIA</td>
<td>Population-Based HIV/AIDS Impact Assessment</td>
</tr>
<tr>
<td>PLHIV</td>
<td>People Living with HIV</td>
</tr>
<tr>
<td>PMTCT</td>
<td>Prevention of Mother-to-Child Transmission</td>
</tr>
<tr>
<td>PPP</td>
<td>Public-Private Partnership</td>
</tr>
<tr>
<td>PrEP</td>
<td>Pre-exposure Prophylaxis</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TLD</td>
<td>Tenofovir, Lamivudine, and Dolutegravir</td>
</tr>
<tr>
<td>TPT</td>
<td>TB Preventive Treatment</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>Joint United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>VACS</td>
<td>Violence Against Children Surveys</td>
</tr>
<tr>
<td>VL</td>
<td>Viral Load</td>
</tr>
<tr>
<td>VLS</td>
<td>Viral Load Suppression</td>
</tr>
<tr>
<td>VMMC</td>
<td>Voluntary Medical Male Circumcision</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
A mother with her child in Mozambique.

Photo courtesy of USAID